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ABSTRACT

DETERMINING HAPLOTYPE SPECIFIC X CHROMOSOME INACTIVATION
STATE AND RELATED EPIGENETIC FEATURES IN FEMALE X-LINKED GENES
Ariah Dawn Mackie

Females with heterozygous X-linked mutations are prone to pseudo-haploinsufficiency
because random X chromosome inactivation (XCI) silences one of their two X
chromosomes. A prior study explored the theory that reactivating the silenced healthy
allele could be a treatment for pseudo-haploinsufficient females. The next step was to
evaluate this approach in a clinically relevant stem cell model of the rare neurological
disease CDKL5 Deficiency Disorder (CDD). It was necessary to validate X-inactivation
state with respect to CDKL5 allele expression in one of these models. We explored
CDKL5 allele expression in two populations of CDD female patient-derived induced
pluripotent stem cells (iPSCs) by determining whether expression of the CDKL5 allele
from the inactive X chromosome was the result of a mixed population or incomplete
XCI. To examine incomplete XCI due to naïve cell state, the iPSCs were differentiated
into neuronal stem cells (NSCs), but sequencing revealed that NSCs maintained inactive
allele expression. By contrast, sequencing of individual clones selected from both iPSC
populations revealed clonal expression of CDKL5 alleles. This result indicated that a
mixed cell population was the likely cause of "inactive" allele expression. This supports
the use of these particular iPSCs as reactivation models. To develop a pipeline to observe
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epigenetic states on the inactive X, standard bioinformatic analysis of ChIP-seq data was
combined with AlleleSeq to assess allele specific activity. This pipeline was used on
publicly available ChIP-seq data from GM12878 cells. The results reveal bottlenecks for
allele specific epigenetic research. Collectively, this work contains both methods and
considerations for researchers studying inactivation of specific X-linked genes in iPSC
models and epigenetic features in the female X chromosome.
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1
BACKGROUND AND SPECIFIC AIMS
Introduction

Dosage compensation of X-linked genes in females occurs via random Xchromosome inactivation (XCI) (Lyon 1962). Because XCI is random and the probability
of silencing either parental X is equal, females are functional mosaics that express either
the maternal or paternal X in each of their cells. Thus, if a heterozygous mutation is
present, approximately 50% of cells will express the healthy allele. In the case of a loss
of function mutation, limited transcriptional availability of the healthy allele can result in
pseudo-haploinsufficiency. XCI plays a key role in the presentation of X-linked diseases
because it determines which allele is expressed in each cell in females.
One treatment approach is to selectively reactivate the silenced, healthy allele by
changing its epigenetic signature. This strategy involves inducing epigenetic
modifications to the allele that mimics the epigenetic changes that occur during XCI
escape, a natural phenomenon that allows for low-level expression of genes on the
inactive X (Xi) (reviewed in Fang et al. 2019). There are several factors that can act as
fail-safes to prevent severe disease including XCI skewing, intracellular sharing, and XCI
escape. The last of these events, XCI escape, can be mimicked artificially by inducing
epigenetic change and might be a potential treatment for female patients with X-linked
intellectual disabilities (XLID) (Halmai et al. 2020, Bhatnagar et al. 2014, Carrette et al.
2018). Recently, targeted escape with CRISPR dCas9 tools have reactivated silenced X
allele expression in a neuronal cell line (Halmai et al. 2020). Patient iPSCs could be an
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important model system to evaluate whether gene reactivation improves cell health.
Moreover, a close examination of the epigenetic signature present on inactive and escape
genes could be informative for future targeted reactivation experiments.
Mechanisms in female X-linked disorders
The development of X-linked disorders differs between the sexes both because of
male hemizygosity and female XCI. Males are usually more severely affected by Xlinked mutations because they only possess a single X-chromosome. A mutation that
would not result in a noticeable phenotype in a heterozygous female can be severely
harmful in a male. For example, a mutation in the gene that causes Nance-Horan
Syndrome (NHS), causes slight vision loss in females while males experience severe
vision loss and microphthalmia(Migeon et al. 2020) . By contrast, the phenotype caused
by an X-linked mutation in a heterozygous female can range from no observable effect to
severe disability. This broad range of outcomes is a direct result of the X chromosome,
whether or not it escapes X chromosome inactivation, and several compensatory cellular
mechanisms (reviewed in Migeon 2020).
For a heterozygous female with an X-linked mutation, her eventual phenotype
depends not only on the gene affected and the severity of the mutation but also on X
chromosome inactivation and to what extent there is skewing that favors the healthy
allele (Migeon et al. 2020). This process begins in the first week of embryonic
development (Petropoulos et al. 2016). One X chromosome in each embryonic stem cell
goes through a series of repressive epigenetic changes when the expression of
pluripotency genes begins to decrease (Wutz and Jaenisch 2000; Schultz et al. 2014).
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XCI is initiated by the expression of the long noncoding RNA X Specific Inactive
Transcript (Xist) and mediated by XACT (Vallot et al. 2017; reviewed in Bonora and
Disteche 2017; Borsani 1991; Brockdorff et al. 1991). Xist coats the pre-Xi and recruits
epigenetic editors that modify the DNA and surrounding histones (reviewed in Pontier
and Gribnau 2011). By contrast, XACT appears to limit the silencing ability of Xist by
antagonistically mediating the deposition of Xist on the inactive X (Vallot et al. 2017).
The process of epigenetic changes initiated by the deposition of Xist begins with the loss
of activation marks like acetylation (H3K27ac) and H3K4me2 with the concurrent gain
of repressive markers like H3K27me3 and H2AK119u. Histone 2a (H2a) is later replaced
with macroH2a and CPG islands are methylated. This is followed by the accumulation of
H2K9me3 and H4K20me3 (Bonora and Distche 2017).
All of these epigenetic changes assist in the formation of a compact
heterochromatic Barr body, which suppresses transcription of most genes on the Xi. The
final outcome of this is almost complete silencing of one X in each cell. This 50/50 ratio
of Xm/Xp (X maternal/X paternal) silencing is then inherited in all daughter cells. In the
context of a mutation, random X inactivation results in approximately half of cells
expressing the mutant allele and the other half the healthy allele. This means only half of
all cells in a given tissue express the healthy allele. This reduced total expression of the
healthy allele can result in haplo-insufficiency.
Sometimes XCI skewing, where one parental X is overrepresented as Xi, can
ameliorate the effects of a loss of function mutation(Migeon et al. 2020). XCI skewing
can occur both via negative selection and randomly during embryogenesis. Negative
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selection can occur if a mutant allele on the active X (Xa) causes cells to fail to divide as
successfully as wildtype expressing cells (reviewed in Migeon 2020). This selection
process results in a skewed population where the healthy allele is usually on the active
chromosome. However, the rate of selection varies depending on how pathogenic the
mutation is to the cell (reviewed in Migeon 2020). Skewing can also occur when XCI is
initiated. It is estimated that nearly 50% of females have skewed X chromosome
expression in which one allele accounts for 65% or more of total expression (Shvetsova
et al. 2019). This might come as a surprise given XCI operates with the same probability
as a coin flip. However, this can be explained theoretically given the number of cells that
would give rise to a certain germ layer. The perfect 50/50 ratio of silenced Xm to Xp is
what would be expected if a large number of cells were present when germ layers are
established. However, as X inactivation occurs at approximately the 8-cell stage of
embryonic development, there is likely to be skewing (reviewed by Panning 2008; Berg
et al. 2009; Shvetsova et al. 2019). If skewing favors healthy allele expression enough to
support homeostasis, pseudo-haploinsufficiency and resulting disease symptoms can be
ameliorated.
Similarly, a third mechanism that can help alleviate the effect of an X-linked
mutation by increasing healthy allele expression is XCI escape. Genes that experience
XCI escape, termed escapees, have low levels of expression because they have a unique
epigenetic signature(reviewed in Berletch et al. 2011; Balaton and Brown 2016; reviewed
in Migeon 2020). One example of how XCI escape can affect disease outcomes is in
Orofacial Digital Syndrome (OFD1) patients, who have a loss of function OFD1 allele.
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Normal karyotype human males with loss of function of OFD1 die in utero. In contrast, a
woman with a heterozygous OFD1 can expect to live into her 40s. This discrepancy
would appear to be merely the result of expression of the healthy allele from the active X.
However, a look at outcomes of this mutation in mice reveals this is not the case. Female
mice die shortly after males when they are still neonates because OFD1is not an escape
gene in mice. By contrast, human females survive into adulthood because OFD1 partially
escapes silencing to different degrees in different tissues in humans (reviewed in Franco
and Thauvin-Robinet 2006; reviewed in Migeon 2020; reviewed in Pezella et al. 2022).
Transcription in escape genes is possible because they have different
characteristics than silenced genes including proximity to other escape genes and XIST,
histone modifications, and CpG methylation. Overall, these gene regions resemble areas
that normally undergo transcription (Balaton and Brown 2016; Fang et al. 2019).
Numerous factors can determine whether a gene is destined for escape. The first factor is
proximity to LINE elements, Xist deposition, and other escape genes (Sousa et al. 2019).
Escape genes in humans normally appear together in blocks (often in the pseudo
autosomal region) rather than individually dispersed around the genome (Tsuchiya et al.
2004; reviewed in Prothero et al. 2009; Berletch al. 2011; Fang et al. 2019). Escapees are
also enriched for marks that support transcription, such as acetylation and H3K36me3
(Sousa et al. 2019). They lack repressive marks like H3K27me3 (Sousa et al. 2019;
reviewed in Disteche and Berletch 2015; Fang et al. 2019). Hypomethylation of genomic
CPG islands is also an indicator of escapee status (Cotton et al. 2015; Fang et al. 2019).
However, the pattern of hypomethylation and its association with escape seems to be
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region-specific. Loss of methylation particularly within 1 kb of the transcription start site
is inversely correlated with expression (Sharp et al. 2011).
Of the aforementioned mechanisms that can alleviate the effects of an X-linked
mutation, XCI escape might be potentially valuable for treating X-linked disorders in
females. The goal is to allow escape in the healthy allele in order to ameliorate the effects
of a loss of function mutation in the diseased allele. Research on targeted editing of
epigenetic marks and the characteristics of escapee genes have helped further the goal of
artificially inducing escape. Epigenetic features like CpG island methylation and histone
modifications allow for transcription in escape genes. These features are also editable and
mimicking these features in silenced genes can cause an escape state (Halmai et al. 2020).
Current work to treat X-linked disorders focuses on inducing artificial X-reactivation by
mimicking the epigenetic state of natural escape genes.
The potential of artificial X reactivation as a treatment for X-linked genetic disorders.
The earliest artificial escape methods were small molecule interventions that
relied on passive reactivation of genes and caused global reactivation (Venolia et al.
1982; Hansen et al. 1998). This includes the disruption of methyltransferases to passively
induce demethylation and inhibiting factors involved in X inactivation (Venolia et al.
1982; Hansen et al. 1998; Bhatnagar 2014). Now, one current strategy used to induce
XCI escape is demethylation at CpG island promoters (Halmai et al. 2020; Liu et al.
2016; Liu et al. 2018; Carrette et al. 2017). This can be done either through interfering
with the function of DNA methyltransferase or by specifically demethylating the DNA
directly. DNA methylation is placed by DNA methyltransferase 3a/b (DNMT3a/b) and
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maintained by DNA methyltransferase 1 (DNMT1) (reviewed in Moore et al. 2013).
Inhibition of DNMT1 causes passive demethylation and subsequent non-targeted global
reactivation of genes on Xi. Cytosine analogues like azacytidine and 5-aza-2'deoxycytidine passively demethylate CpGs through the inhibition of DNA
methyltransferases. These compounds are recognized and used by DNA polymerase
during DNA replication to replace cytosine in the nascent DNA strand. DNMT1
recognizes this cytosine substitute alongside guanine nucleotides as CpGs. DNMT1 then
binds to the pseudo-CpG and creates a covalent bond between the analogue and itself via
nucleophilic attack. Normally, if the DNA methyltransferase is interacting with a regular
nucleotide, this covalent bond will eventually be destroyed via the elimination of the 5th
carbon of cytosine. However, derivatives of these cytosine analogues have a nitrogen in
place of the carbon, so the DNA methyltransferase remains bound and unable to continue
its function. This dilutes the pool of DNA methyltransferases available to methylate CG
dinucleotides (reviewed in Stresemann and Lyko 2008). 5-aza-2’-deoxycytidine has been
used for global reactivation of X linked genes on the silenced X chromosome and lacks
loci specificity (Hansen et al. 1998). It acts globally without loci specificity because it
affects the total pool of all DNA methyltransferases in the cell. This can cause
demethylation anywhere in the genome.
There are other general strategies for initiating X reactivation. One is to target
important long-coding RNAs or epigenetic effectors that play a role in XCI. Antisense
oligonucleotides (ASOs) are an effective tool for specifically inhibiting gene expression.
Given homology to a target mRNA one of the functions of ASOs is that they can bind
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their target to either inhibit its translation or cause its degradation by recruiting
hydrolyzing enzymes (Atri et al. 2019). Another potential therapeutic approach to
reactivate methyl-CpG binding protein 2 (MECP2), an X-linked gene that is mutated in
Rett Syndrome, is by combining ASO targeting Xist in combination with 5-aza-2'deoxycytidine (Carrette et al. 2018). A similar strategy is to use RNA interference to
screen for trans-acting factors that are needed for XCI. These trans-acting factors
typically promote expression of Xist or assist in its localization to Xi. Some trans-acting
factors cause reactivation of Xi when they are targeted with small molecule inhibitors
(Bhatnagar et al. 2014). Both of these approaches are limited by targeting mechanisms
that occur upstream of XCI epigenetic modifications. This makes specificity a challenge
because trans-activating factors, such as DNMT1, do not operate in a loci specific
manner. Interference with factors is likely to cause widespread genetic modifications.
In contrast to the aforementioned methods that cause global epigenetic changes
across the entire genome, dCas9-based epigenetic effectors can target specific loci. This
targeting specificity has therapeutic potential for the treatment of X-linked disorders
because it can alter the expression in a gene of interest without altering activity in other
genes. Ten-eleven translocation methylcytosine dioxygenase 1 (TET1) actively
demethylates cytosine by converting methylated cytosine to 5-hydroxymethylcytosine (5hmC). TET1 then oxidizes 5-mC to 5-fluorocytosine (5fC) and 5-carboxylcytosine
(5caC). These latter two modified cytosines are excised via the Thymine DNA
glycosylase (TDG) pathway and then replaced with cytosine via base excision repair (Wu
and Brenner 2014). Linking the TET1 catalytic domain with dCas9 allows for this direct
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modification of cytosine in loci specific manner because dCas9 acts as an anchor that can
be specifically localized to a genomic region that matches a guide RNA (Liu et al. 2016;
Halmai et al. 2020). Moreover, because the mechanism of TET1 does not rely on DNA
replication, demethylation is possible in non-dividing cells like neurons.
This is especially advantageous for X-linked disorders that affect the central
nervous system such as CDKL5 Deficiency disorder (CDD), a disease characterized by
developmental abnormalities and severe epilepsy. In 2020, dCas9 combined with the
epigenetic effector TET1 and the trans-activator VP64 was used to reactivate CDKL5
from the silenced allele (Halmai et al. 2020). Researchers targeted dCas9-TET1CD to the
promoter region of cyclin-dependent kinase-like 5 (CDKL5) to induce demethylation.
This resulted in silenced allele expression compared to mock treated cells (cells treated
with diluted transfection reagents only). Alongside dCas9-TET1CD, they used VP64 to
upregulate the expression of silenced CDKL5 (dCas9-VP64) to potentiate the effects of
dCas9-TET1CD. The combination of TET1CD and VP64 with dCas9 (VP64-dCas9TET1CD) raised silenced CDKL5 allele expression to greater than 60% of that on Xa in a
neuronal cell line (Halmai et al. 2020).
Patient-derived iPSCs as a model system for allele-specific X reactivation
In order to further explore reactivating CDKL5 as a therapy for CDD, recent work
has focused on how to model this disease in vitro. One model system that has been
considered is patient-derived induced pluripotent stem cells (iPSCs). CDD iPSCs are an
attractive model system because it matches the genotype of the patient. As CDD
principally affects the central nervous system, neurons derived from these iPSCs are
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useful for modeling whether these therapies improve neuronal health. Neuronal cells
derived from CDD iPSCs have aberrant cell health including differential protein
expression compared to healthy controls, increases in mitochondrial depolarization, and
DNA fragmentation. Differentiated neurons also had hyperactive electrical activity and
malfunctioning sodium and potassium ion channels (Negraes et al. 2021). Electrical
hyperexcitability is a characteristic of epilepsy, which CDD patients suffer from (Telias
et al. 2022). Thus, these cells seem to recapitulate cellular conditions in CDD patients.
An ideal test model system would also have stable XCI. This means that expression in
silenced genes would always correspond to only one allele on Xa. If the silenced allele is
the healthy allele, clonality makes it possible to ascertain that an increase in healthy allele
expression is due to changes on Xi. By contrast, a mixed population of cells without a
clonal state introduces ambiguity because there would always be background expression
of both alleles. This issue of stable XCI is a concern in iPSCs
There is conflicting information about whether XCI is maintained in human cells
during somatic cell reprogramming into iPSCs. Two possible scenarios have been
reported: XCI maintenance and Xi reactivation. In the first scenario, if X silencing is
stable, clonal expansion of a single stem cell will render a clonal cell population that has
monoallelic expression for X-linked genes. This is the desirable condition if one wants to
test changes in allelic expression after targeted gene reactivation. As an example of stable
XCI maintenance, several groups have successfully created isogenic populations with
monoallelic expression in iPSCs derived from Rett Syndrome patients because no
apparent reactivation occurred during reprogramming (reviewed in Cheung et al. 2012;
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Ananiev et al. 2011; Amenduni et al. 2011; Pomp et al. 2011). However, other studies
have observed reactivation of Xi during reprogramming in Rett iPSCs (Kim et al. 2009;
Marchetto et al. 2010). iPSCs with reactivated Xi experience random X inactivation again
during differentiation (reviewed in Cheung et al. 2012). This can make creating an
isogenic population challenging if the differentiated cell type is not easily expandible
from a single cell.
Though it is still too early to determine the exact mechanics of X reactivation in
human iPSCs, there is evidence to suggest X reactivation might be caused by the
epigenetic changes that occur during reprogramming. In general, during reprogramming
iPSCs have changes in DNA methylation and histone modifications. In mice, X
chromosome reactivation actually must occur to create a pluripotent cell (reviewed in
Rebuzzini et al. 2020). During mouse iPSC reprogramming, Cadherin-1 becomes
upregulated by the expression of OSKM factors (OCT4, SOX2, KLF4, CMYC)
(reviewed in Rebuzzini et al. 2020). Nanog later becomes reactivated and with its
reactivation: Xist expression is repressed, the mouse X activating gene Tsix is activated,
and DNA demethylation occurs (Janiszewki et al. 2019; Pasque et al. 2014). After DPPA
and PECAM1 are reactivated several chromatin changes finally completely reactivate Xi
(reviewed in Rebuzzini et al. 2020). How much of this also plays part in human iPSC
reactivation remains to be determined.
Another obstacle that can occur with an iPSC model is XCI erosion. XCI erosion
is when there is partial loss of XCI when iPSCs are maintained long-term in culture. Both
human iPSCs as well as ESCs are known to have potentially unstable XCI (reviewed in
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Brenes et al. 2021). iPSCs can lose H3K27me3 and Xist lncRNA after being passaged for
a long period due to XCI erosion (Anguera et al. 2012; Dandalekis et al. 2016;
Mekhoubad et al. 2012). Cells with lower Xist expression are more likely to experience
erosion. This erosion can have a significant effect on the proteome of the affected cells
(reviewed in Brenes et al. 2021). Normally because of dosage compensation, male and
female transcription levels of X-linked genes are similar. In eroded cells, this even
dosage is lost: eroded female cells can express X proteins at levels that are 27% higher
than what would be found in male cells (reviewed in Brenes et al. 2021). XCI erosion is
therefore detrimental to CDKL5 (and in general X-linked) disease modeling in two ways.
First, there is a possibility that a gene meant for reactivation with targeted reactivation
(i.e., CDKL5) will get spontaneously reactivated due to erosion. The other shortcoming
is the possible changes in global gene expression do not naturally mimic in vivo
conditions. With this comes the difficulty of determining whether any phenotypic
changes are downstream of epigenetic tools or just broad transcriptional changes induced
by erosion.
Methods of allele specific epigenetic analysis to determine epigenetic signatures on the
inactive X
Close analysis of the epigenetic signature in natural escape and silenced genes on
Xi could inform what level of artificial modification is needed to induce escape for
therapies. However, to be able to observe only the epigenetic state that is on Xi, one has
to be able to determine whether a modification is present on Xa or Xi via the genomic
differences between the two alleles. The method to solve this problem is called allele
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specific epigenetic analysis. Allele specific epigenetic analysis for the X chromosome
depends on two prerequisites. First, epigenetic marks can only be determined allelically if
they occur near a heterozygous single nucleotide polymorphism (SNP) or other
heterozygous genetic variant. Second, a population of cells must be clonal with respect
to which parental allele is Xi.
SNPs are vital because if the parental origin of each SNP is known, reads that
pass over these SNPs can be aligned to the appropriate parental X chromosome.
Clonality is important because it allows one to ascertain whether an epigenetic mark is on
Xi based on the parental alignment. In the case that an epigenetic mark does not pass
over a heterozygous SNP, alignments will only show accumulated signal for both Xi and
Xa. Overcoming this accumulated signal as much as possible is the main value of allelespecific epigenetic analysis. If one does not classify the parental origin of epigenetic
reads, the epigenetic state on Xi can be masked by the transcriptionally active epigenetic
marks on Xa. Allele-specific epigenetic analysis alleviates this masking.
A variety of bioinformatic tools have been developed for allele-specific epigenetic
analysis (Table 1). Most of these pipelines focus on heterozygous SNPs as described
above. AlleleSeq expects a phased diploid genome built from a variant call file as its
input (Rowzosky et al. 2011). ALEA and its descendent MEA construct a genome using
SNPs as part of their pipeline (Younesy et al. 2014; Albert et al. 2018). All three of these
tools then have strict alignment settings to specifically map to one allele. SNPsplit, which
allows a set of alignments to be sorted into two files specific for each allele, relies on
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receiving alignments that were performed on a phased genome or an N masked (N is
substituted where SNPs are present) one (Krueger and Andrews 2016).
AlleleSeq maps both ChIP-seq and RNA-seq reads to their maternal or paternal
chromosomal origin to generate the allelic mapping frequency at each heterozygous SNP.
Reads are first filtered to remove N values and trimmed to remove read-end errors.
AlleleSeq then performs an alignment with Bowtie (Langmead et al. 2009) to both the
maternal and paternal chromosome of a personalized phased genome. This Bowtie
alignment is set to report mappings that are unique hits with the least number of
mismatches. It prohibits alignments with more than two mismatches. Alignments are then
pooled into a set in which each read will be represented by either a maternal or paternal
alignment based on which alignment has the fewest number of mismatches. AlleleSeq
then takes a list of heterozygous SNPs and generates a file that lists the number of
maternal and paternal alignments at each SNP location. SNPs that appear to be near Copy
Number Variants (CNVs) are excluded. In this case, a CNV is assumed to be a region
where the read depth is <1 or >3 in the genomic data that was used to build the
personalized genome (Abyzov et al. 2011).
If AlleleSeq is provided with a Browser Extensible Data (BED) file that shows
regions of binding or gene locations, it will call an allele specific event if there is
significant skewing to one parental allele in a given locus. The threshold for skewing is
calculated first by generating a P value from a binomial test assuming there is a 50/50
probability that reads will align to either parental allele. Multiple hypothesis testing is
then corrected for using a False Discovery Rate (FDR) threshold. AlleleSeq computes the
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FDR by going over each SNP location and randomly assigning each mapped read to an
allele. The number of false-positive allele specific events (i.e., skewing) is estimated with
this stimulation. FDR is then calculated by dividing the number of false positives with the
number of observed positives. “True” allele-specific events are called if the FDR is less
than 10%, a setting AlleleSeq has as a default.
The first publication on AlleleSeq tested its ability to perform global allelespecific analysis from data derived from work with the GM12878 lymphoblast cell line
(Rozowsky et al. 2011). GM12878 was derived from a Utah woman of western
European ancestry as part of the ENCODE (Encyclopedia of DNA Elements). GM12878
is an ideal cell line for X chromosome allele-specific analysis for several reasons. Both
the individual genome (NA12878) and the genome of both parents are in the public
domain. With a variant call file (VCF) derived from this information, Rowzowsky et al
built a publicly available phased genome of NA12878. Another benefit of GM12878 is
that X inactivation is stable because these are somatic cells (unlike iPSCs). As long as a
single cell clonal selection is performed on this cell line, one should be able to determine
what occurs on Xi by locating an epigenetic event to a parental allele.
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Table 1 - Tools for Allele-Specific Analysis
Name

Strategy

Output

Use Case

Allele-Seq

Aligns reads to both chromosomes
on a pre-prepared phased diploid
genome. Reads are assigned to
maternal or paternal alleles based
on the least number of
mismatches.

count of how
many reads map
to each allele at
all heterozygous
SNPs

ChIP-seq

DAMEFinder

Allows comparisons of allelespecific methylation in two
samples exposed to two different
conditions. Computes allele
specific methylation score for
every CpG in both samples and
compares the difference. CpG sites
that cluster nearby that also change
significantly between conditions
are recorded.

returns clusters
of CpG sites
that vary greatly
between two
samples

bisulfiteseq

ALEA

Constructs a phased diploid
personal genome using whole
genome sequencing reads and
haplotypes from the 1000 genomes
project. ChIP-seq reads are then
aligned to this phased genome and
reads that specifically align to one
heterozygous SNP are kept. These
heterozygous SNP alignments are
displayed on a reference genome
in a Wiggle track.

two wiggle
track files
displaying
haplotype
specific ChIPseq alignments
that can be
viewed on IGV
or the UCSC
genome browser

ChIP-seq

MEA

MEA operates like ALEA, but
uses Bismark for bisulfite-seq
alignments

allele-specific
DNA
methylation
maps

bisulfiteseq and
ChIP-seq

SNPsplit

After reads have been aligned to
genomes with SNP that have been
masked, SNPsplit sorts alignments
by their allelic origin

alignments are
sorted into
allele-specific
files

bisulfiteseq and
ChIP-seq

iAseq

iAseq is intended for use with
multiple ChIP-seq data sets to fix
the issue of low statistical power in
allele-specific ChIP-seq results. It
uses Bayesian hierarchical mixture
model. It allows one to look at the

correlation of
allele-specific
binding across
different
proteins/experi
ments

ChIP-seq

Notes
pipeline requires
parental genotypes
to define the
parental origin of
heterozygous
SNPs
Does not require
SNPs to assess
allele-specific
methylation. Has
been tested on
female and male
chromosomes and
can distinguish
chromosomes by
sex based on
methylation
differences.

Second version of
ALEA, Docker
engine is highly
recommended for
installation.
intended for
mouse data, using
it for human
requires direct
editing of source
code in Perl
requires
understanding of
advanced statistics
and probability
techniques
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Name

Strategy

Output

Use Case

Notes

correlation of allele-specificity of
multiple ChIP-seq targets at once.

methHaplo

methPipe

methHaplo identifies regions with
allele-specific DNA methylation
using SNPs like other allelespecific methylation tools. Its
unique feature is it can combine
this with HiSeq data to find larger
haplotype regions.
Methpipe is a large set of tools
designed for whole-genome
bisulfite sequencing analysis
WGBS - it offers three methods:
allelicmeth, amrfinder, and
amrtester. Methylation of reads are
counted and how dependent these
are on nearby CpGs is used to
estimate the probability of allelespecific methylation in a region.
Allelelicmeth gives allele-specific
methylation scores for every CpG.

creates
graphical
figures

probability of
allele-specific
methylation in a
specific locus,
allele-specific
methylation
counts at each
CpG

bisulfiteseq

bisulfiteseq

it's recommended
that you have 10x
coverage in your
bisulfite seq
alignments and
that reads are
100bp before
trying the allelespecific analysis
tools
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Prior work and unknowns for studying targeted reactivation
Prior work has shown that targeted reactivation of silenced X alleles is possible.
Using these approaches to turn on healthy silenced X-linked alleles might be a treatment
for females with X-linked disorders (Halmai et al. 2020). Robust testing of these
approaches requires both model systems and bioinformatics pipelines that have been
vetted for the purpose of studying the inactive X chromosome. The purpose of this
vetting is to eliminate the noise of gene expression and epigenetic features that occur on
Xa from Xi chromosome signal. This places stringent demands on which tools and model
systems can be used.
Patient-derived iPSCs are an attractive model system for studying X-linked
disorders. iPSC pluripotency makes it possible to grow neuronal cells, the affected cell
type in X-linked Intellectual Disabilities like CDKL5. iPSC cells will have a matching
genotype and disease-causing mutation to the patient they were derived from. However,
as described previously, XCI is not always stable in iPSCs and it is unclear why only
some iPSCs lose XCI stability. Other than being an unanswered biological question, XCI
instability in iPSCs is a practical problem for studying reactivation. Unstable XCI makes
it impossible to determine whether changes in expression are the result of targeted
reactivation or iPSC reprogramming. It is therefore necessary that any prospective cells
be evaluated for stability.
Recent work in a set of CDKL5 patient iPSCs illustrates how the issue of
ambiguous XCI instability can arise. Two populations of iPSCs were acquired for the
purpose of testing targeted reactivation using dCas9 epigenetic tools. These two cell

19
populations (Man0855-01 mutant and wildtype) were the result of single-cell clonal
expansion derived from a female patient (Chen et al. 2021). Because of clonal selection,
these cells were predicted to have isogenic expression of one CDKL5 allele each (one
population would express only mutant and the other wildtype). However, initial
sequencing of CDKL5 allele expression in both cell populations revealed that about 8%
of transcripts matched the allele on the inactive X.
This “silenced” allele expression was hypothesized to be either caused by a mixed
population of cells or incomplete or eroded XCI because of iPSC XCI instability (Vallot
et al. 2017). If the cell population was not clonal because of mixed population, a second
round of single cell expansion would be needed prior to reactivation experiments. This is
necessary because one needs clonal populations (or single cells) to do allele-specific
analysis of the silenced X chromosome. In other words, Xi must be the same parental X
in all cells so that an event (whether that be expression or an epigenetic mark) on one
parental chromosome can be mapped as an event on Xi. The second possibility was that
XCI was unstable in these cells, which would make them an inappropriate model system
for X reactivation. Both of these hypotheses had to be evaluated for work to proceed.
The second need for studying targeting reactivation is defining which
bioinformatics tools are appropriate for studying the silenced X chromosome. The ability
to look at the epigenetic state of the inactive X during studies might offer insight about
which levels of marker enrichment result in escape or silenced states. For X reactivation
experiments with dCas9 epigenetic tools, a snapshot of epigenetic features in untreated
versus treated cells an serve as experimental feedback. Ideally, a researcher would be
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able to easily view the change in histone marks specifically for the gene in question. They
would be able to answer the question of how much change occurred, where it occurs in
the gene, and whether off-target changes are present. They would be able to compare this
to the level of expression changes. Another key benefit of having vetted pipelines to
study the silenced X is to define the range of epigenetic signatures in natural escape and
silenced X linked genes.
This general research can be informative for future targeted reactivation therapies
because these therapies aim to engineer the epigenetic states found in natural escape
genes. Generally speaking, there are two types of gene epigenetic signatures possible on
Xi. Compared to silenced genes, escape genes tend to have hypomethylated promoters
and a loss of silencing histone marks. A binary classification of epigenetic signatures
(enriched or not enriched) is useful as a model for understanding why a gene might
escape inactivation. However, genes are not binary on and off switches. Rather, genes on
Xi experience an analogue range of epigenetic signatures. This range of signatures is
likely to correspond to a range in expression levels on Xi just as it does in other
chromosomes. For example, methylation on the first exon of a gene has a quasi-linear
inverse correlation with expression (Anastasiadi et al. 2018). This analog perspective of
gene silencing in escape and silenced genes is more useful for reactivation therapies
because it can address the possibility of overexpression. There likely exists an ideal level
of epigenetic modifications that will allow for reactivation without causing over
expression.
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Many general bioinformatics tools exist for the analysis of epigenetic markers on
genes, however, any researcher seeking how to use these tools for the purpose of
specifically looking at female X-linked genes would find a dearth of information on how
to concretely do this. A useful guide for ChIP-seq analysis would answer several
questions: which experimental conditions are appropriate, the number of reads needed,
how high sequencing has to be, how to access the quality of the ChIP-seq, and most
importantly how to distinguish markers on Xi from that of Xa. With this knowledge,
analysis on the differences between escape and natural genes would be accessible to
researchers.
Specific Aims

Targeted reactivation of inactivated X-linked alleles might help treat X-linked
disorders by restoring wildtype or healthy gene expression in variant expressing cells.
The overall aim of this work is to address two hurdles for studying targeted reactivation:
the lack of consensus on the stability of XCI in patient stem cells and standards for
assessing epigenetic modifications on Xi. This study addresses these issues through the
following two aims.
Aim 1: to evaluate the state of X inactivation in CDKL5 patient iPSCs and NSCs
The purpose of this aim is to determine whether expression coming from the
“inactive” allele in Man0855-01 iPSCs was the result of a mixed population or whether
expression was the result of a partial loss of XCI. The first hypothesis, that the reads
representing CDKL5 expression coming from the inactive allele were the result of a
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mixed population of cells, was evaluated by assessing allele expression after single clone
expansion from the parental population of iPSCs. The second hypothesis, which
suggested that XCI was incomplete in these iPSCs because of their pluripotent state, was
tested by assessing CDKL5 allele expression in neural stem cells differentiated from the
iPSCs. To assess allele expression accurately in both cell types special attention was
taken to remove the possibility of genomic contamination in samples. A double RNA
extraction was performed first by selecting RNA from a phase separation caused by
chloroform that was added to cell lysates and Trizol and then by further purifying phaseseparated RNA using a Direct-zol Zymogen RNA extraction kit. CDKL5 cDNA that was
reverse transcribed after RNA extraction were amplified using exon spanning primers
and then size selected via gel electrophoresis. The two part RNA extraction was used
after prior preparations resulted in aberrant skewing (such as more mutant reads in
wildtype skewed lines). This was thought to be caused by overloading the Direct-zol kit
column. Adding a phased extraction resolved this issue. Amplicons were then barcoded
to distinguish between samples during multiplexing and sequenced at the Massachusetts
General Hospital Center for Computational Biology. Reads were processed to determine
the ratio of wildtype and mutant reads in both iPSCs and NSCs.
Aim 2: define methods to analyze histone modifications on escape and silenced genes on
Xi.
The goal of aim 2 was to combine published tools into a protocol for looking at
epigenetic features of different genes on Xi and to test these approaches on open-source
data. To create this protocol, universal standards of assessing ChIP-seq were combined

23
with approaches to look at allele-specific events. The process is broken into multiple
steps: experimental requirements, assessing the quality of immunoprecipitation and
sequencing, visualizing mapped reads, and finally setting up a tool for allele-specific
analysis. Much of this work focuses not just on the general recommendations but also
how these tools are used on a command-line interface.
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AIM 1: EVALUATING THE STATE OF X INACTIVATION IN CDKL5 PATIENT
IPSCS AND NSCS
Introduction

Dosage compensation of genes located on the X chromosome in females occurs
through random X chromosome inactivation (XCI) at approximately the 8-cell stage of
embryonic development (reviewed by Panning 2008; Berg et al. 2009). XCI is initiated
by the long noncoding RNA X-inactive Specific Transcript (Xist), which acts as a
scaffold for epigenetic effectors to coat the pre-inactivated X (reviewed in Vallot et al.
2016; reviewed in Bonora and Disteche 2017; Borsani et al. 1991; Brockdorff et al. 1991;
Brown et al. 1991; reviewed in Pontier and Gribnau 2011). These effectors initiate
histone modifications and DNA hypermethylation, both of which favor a transcriptionally
silent state in the inactivated X (Xi) (reviewed in Bonora and Disteche 2017).
During this process, the maternal and paternal X (Xm and Xp) have an equal
probability of silencing in each cell (reviewed in Wutz and Gribnau 2007). This parental
silencing pattern is then maintained in daughter cells (reviewed in Panning 2008). Due to
random XCI, female tissues have mosaic expression of X-linked genes. Half of their cells
express the maternal and the other half express the paternal X. This mosaicism plays a
key role in the development of X-linked disorders in females. Due to mosaicism caused
by XCI, a loss of function heterozygous X-linked mutation can result in quasihaploinsufficiency, as only approximately 50% of cells will express the healthy allele and
the other 50% will have mutant allele expression. Reactivating the healthy, but silent
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allele in cells is a potential approach to treat female X-linked disorders (Halmai et al.
2020).
About 10 to 15% of genes on the inactive X are expressed because they have
epigenetic features similar to active genes. This allows them to escape XCI (Carrel and
Willard 2005). Genes that naturally experience escape have a distinct epigenetic signature
that is less compact and transcriptionally active chromatin structure than silenced genes
on the Xi. These epigenetic characteristics include increases in histone acetylation as well
as losses of both histone and CpG island methylation in the promoter (reviewed in
Berletch et al. 2011). Artificially inducing these epigenetic characteristics results in the
expression of silenced X-linked genes (Halmai et al. 2020; Liu et al. 2018; Bhatnagar et
al. 2014). Many of the early approaches to induce escape, such as global demethylation
by inhibiting methyltransferases, operate by inhibiting the endogenous epigenetic
effectors that help maintain X chromosome inactivation. These approaches result in broad
reactivation of X-linked genes rather than at a specific locus. To treat X-linked disorders,
a more targeted approach that acts only on one gene is needed in order to ameliorate
haploinsufficiency in that gene without disturbing expression in other genes.
In 2020, dCas9 fused with an epigenetic effector reactivated the silenced allele of
the X-linked CDKL5 gene (Halmai et al. 2020) in SH-SY5Y neuroblastoma cells. SHSY5Y was used as a cell model because it has a single coding nucleotide polymorphism
within CDKL5, which allows the allelic origin of transcripts to be determined, and
because silenced CDKL5 was not expressed. This guaranteed that any expression from
the silenced allele was the result of epigenetic effector treatment instead of spontaneous
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escape. Researchers used the catalytic domain of CpG demethylase Ten-eleven
translocation methylcytosine dioxygenase 1 (TET1CD) fused to dCas9 (dCas9-TET1CD)
to target the promoter region of CDKL5. With dCas9-TET1CD treatment alone the
percent of CDKL5 transcripts coming from Xi reached 14.5% of total transcripts (Halmai
et al. 2020). In addition to dCas9-TET1, they used the trans-activator VP64 to upregulate
the expression of silenced CDKL5 (dCas9-VP64). TET1 and VP64 with dCas9 (VP64dCas9-TET1), which has been shown to have a synergistic upregulation effect when
combined, raised silenced CDKL5 allele expression to greater than 60% when compared
to Xa (Halmai et al. 2020; Morita et al. 2020).
Defining clonality of X chromosome inactivation in CDKL5 patient-derived iPSCs and
NSCs
Reactivation of CDKL5 with dCas9 tools is a potential treatment for CDKL5
deficiency disorder (CDD) The cause of CDD is loss of function mutations in CDKL5.
Due to random XCI, heterozygous females with this mutation experience insufficient
expression of healthy CDKL5 because the healthy allele is silenced in half of their cells.
Reactivating the healthy silenced allele could potentially alleviate this disease.
As CDKL5 affects the nervous system, the next step to evaluate the therapeutic
potential of silenced CDKL5 reactivation is to work with CDKL5 patient-derived
neuronal cells. iPSCs from CDKL5 patients are an appropriate resource both because
their genotype matches a patient and because of their differentiation capability. Prior
work in neuroblastoma SY-SY5Y cells provided proof-of-concept that CDKL5
reactivation could occur in dividing cells, but they were not derived from a CDD patient.
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By working with neurons derived from patient iPSCs, one can explore if a
treatment is viable in neurons. We received Man0855-01 iPSCs that had been
reprogrammed from a female CDKL5 patient fibroblast cell that had a 1412delA
mutation. These cells had been clonally selected by another lab to form two groups that
would have isogenic expression of only one CDKL5 allele (Chen et al. 2021). The mutant
skewed population was expected to express only the mutant allele of CDKL5. Likewise,
the wildtype skewed population was expected to be clonal for the functional wildtype
allele. The creators of this cell line noted that both XCI state and clonality needed further
assessment (Chen et al. 2021).
Before using these cells as models for targeted X reactivation, CDKL5 allele
expression was assessed in order to confirm that both populations had isogenic
expression of only one allele. The lab sequenced CDKL5 amplicons from mRNA from
two populations of Man0855-01 iPSCs, mutant skewed and wildtype skewed iPSCs, to
determine clonality of CDKL5 allele reads. Amplicons were prepared by first isolating
RNA (Direct-zol RNA Miniprep Plus kit) with an extended 15-minute DNAase treatment
and reverse transcribing these transcripts into cDNA (RevertAid First Strand cDNA
Synthesis Kit (Thermofisher Scientific, Waltham, MA, USA). cDNA was then barcoded
to make multiplexing possible during sequencing (see Methods- Barcode PCR). After
confirming band sizes on a 1% agarose gel, barcoded amplicons were prepped using a
QIAquick PCR Purification Kit (28104) (Qiagen Germantown, Maryland, MD) and sent
to the Massachusetts General Hospital Center for Computational and Integrative Biology
DNA Core for sequencing.
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Sequencing results revealed that each group expressed low levels of the inactive
allele. Specifically, 8.27% of total CDKL5 reads from the wildtype skewed iPSCs were
the mutant allele. Similarly, mutant skewed iPSCs produced 7.51% wildtype CDKL5
reads (Figure 1). This was an unexpected result as the cells had been clonally selected
and CDKL5 is not known as an escape gene. These original wildtypes and mutant
skewed iPSCs were also differentiated into NSCs to compare allelic expression in
differentiated cells because it was believed that “silenced” allele expression could be the
result of naïve iPSC state (Figure 1). This is based on several studies that have shown
that iPSCs can have unstable XCI either through X erosion or the reversal of XCI state
during reprogramming (reviewed in Cheung et al. 2012; Ananiev et al. 2011; Amenduni
et al. 2011; Pomp et al. 2011). The differentiated NSCs that were derived from the mutant
skewed iPSCs had a higher percentage of mutant reads compared to the mutant skewed
iPSCs (t (4) = 44.1404 p = .0001) (i.e., in the NSCs, even more of the total reads were
mutant than in the mutant skewed iPSCs). Mutant reads from the mutant skewed line
increased to 99.56% of total reads, indicating the possibility that these cell populations
might become more isogenic upon differentiation. However, this idea was contested
because there was no significant change in the skewed expression of the wildtype skewed
NSCs compared to wildtype iPSCs (92.1% wildtype reads) (t (4) = 0.5946 p = 0.5841).
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Figure 1: The Average Percentage of Mutant and Wildtype CDKL5 Amplicon
Reads from the Original Man0855-01 iPSCs – Mutant and Wildtype skewed iPSCs and
NSCs were amplicon sequenced prior to clonal selection to establish the baseline expression of
both CDKL5 alleles. a. Average percentage of mutant and wildtype CDKL5 reads in wildtype
skewed Man0855-01 patient derived iPSCs (wildtype reads on the left, mutant on the right) b.
Average mutant and wildtype CDKL5 reads in mutant skewed Man0855-01 patient derived
iPSCs . c. Average mutant and wildtype CDKL5 reads in wildtype skewed Man0855-01 patient
derived NSCs d. Average mutant and wildtype CDKL5 reads in mutant skewed Man0855-01
patient derived NSCs (Credit: Julian Halmai).
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One model to explain the silenced CDKL5 expression is that these cells are still a
mixed population in which both maternal inactivated and paternally inactivated cells are
present despite their earlier selection in which the cells were plated at low density and
then colonies were selected. This is based on prior studies that present both reactivation
of Xi as well as erosion of XCI in passaged iPSCs (Kim et al. 2009; Marchetto et al.
2010; Brenes et al. 2021). A second model is that the low-level expression of the silenced
allele was caused by incomplete or aberrant XCI associated with the pluripotent state in
the iPSCs (Bruck and Benvenisty 2011). This model is supported by the change in
skewing seen between mutant skewed Man0855-01 iPSCs and mutant skewed NSCs
(Figure 1). The percentage of expression from the wildtype allele changed from an
average of 7.51% to less than 1% of total reads in these cells. Loss of pluripotency via
differentiation might have made X inactivation more complete and this could be the
reason why silenced allele expression went down (Bruck and Benvenisty 2011).
The goal of aim 1 was to test whether low expression of “silenced” CDKL5 was
the result of a mixed population of cells or incomplete X inactivation (Figure 2). To test
for a mixed population, colonies were selected from iPSCs that were plated at a low
density and sequenced to measure the percentage of wildtype and mutant CDKL5 reads.
To test if pluripotent state of iPSCs was the cause of XCI skewing, wildtype and mutant
expression were evaluated in NSCs derived from the parent line of iPSCs.
In order to test both these hypotheses, a more rigorous approach to CDKL5
amplicon processing was used for these experiments to rule out the possibility that
silenced allele reads were genomic contamination rather than true expression. Previously,
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amplicons had been produced by lysing cells with Tri Reagent and isolating the RNA
with Direct-zol RNA Miniprep Plus kit. RNA was then reverse transcribed into cDNA
and then sequences were barcoded prior to being sent for sequencing. A chloroform RNA
extraction step was added to this process prior to using the Direct-zol RNA Miniprep Plus
kit. After cDNA synthesis and before the barcoding PCR, cDNA was amplified using
nested exon-spanning PCR and the resulting product was isolated by size on an agarose
gel and purified. This step further helped prevent genomic contamination in the data
because the isolated band size excluded sequences that still contained introns.

Figure 2: Schematic of Aim 1-The goal of aim 1 was to test whether leaky expression of
“silenced” CDKL5 was the result of a mixed population of cells or incomplete X inactivation. If a
clonal selection (an expansion from a single cell) results in clonal expression, this would support
the mixed population hypothesis. If cell expression becomes more clonal as cells differentiate that
would support that XCI is incomplete in these patient iPSCs because of their naive cell state.
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Methods

Clonal selection and expansion of iPSCs
Man0855-01 mutant skewed or wildtype skewed CDKL5 patient-derived iPSCs
(Human Neuron Core Boston Children’s Hospital) were passaged at 80% confluency
from 1 well of a 6 well AggreWell plate (9.6 cm2) (StemCell Technologies, Vancouver,
BC, CA) coated with Corning Matrigel Growth Factor Reduced (GFR) Basement
Membrane-coated Matrix (CB40230) (Fisher Scientific, Waltham, MA, USA) into 3
wells of another coated 6 well AggreWell plate. Cells were maintained in Gibco
StemFlex Complete Medium (A3349401) (Thermo Fisher, Scientific, Waltham, MA,
USA). Single colonies from either mutant or wildtype skewed iPSCs were selected and
expanded into three wells of a six-well plate prior to lysing with TRI reagent (R2073:
Zymo Research, Irvine, CA, USA) or cryo-preserved. Based on the high skewing in both
populations, it was predicted that some of the colonies would be clonal. Thus, multiple
colonies were selected for expansion. During the expansion of colonies, StemFlex
Complete media was changed every other day. Visible signs of differentiation, such as
abnormal morphology or loss of refractive colony borders, were manually removed both
prior to passaging and lysis.
Differentiation of induced pluripotent stem cells into neural stem cells
iPSC colonies were dissociated into a single cell suspension using Gibco™
TrypLE Select 0.75x in PBS (12604021) (Thermo Fisher Scientific, Waltham, MA,
USA). Approximately 10,000 cells per well were plated into an Aggrewell 800

33
Microwell plate (34811) (StemCell Technologies, Vancouver, BC, CA) to form embryoid
bodies (EBs). To maintain cell viability, Y-27632 RHO/ROCK pathway inhibitor
(72302) (StemCell Technologies, Vancouver, BC, USA) was added to the cell suspension
prior to plating at a final concentration of 10 µM. After 24 hours, EBs were replated into
6 well Corning® Costar® Ultra-Low Attachment Multiple Well Plates ( CLS3471)
(MillaporeSigma, Burlington, MA, USA) with 3 ml per well of EB medium (KnockOut
DMEM/F-12 (12660012), 15% Gibco™ KnockOut™ serum replacement (10828028), 1x
MEM non-essential amino acids (11140050), 1x GlutaMax Supplement (35050061), 1
µM 2-Mercaptoethanol (21985023) (Thermo Fisher Scientific, Waltham, MA, USA),
16.7 nM Noggin (6057-NG-100) (R&D Systems, Minneapolis, MN, USA), and 10µM of
SB43152 (1614) (R&D systems, Minneapolis, MN, USA). EBs were plated onto growth
factor reduced (GFR) Corning Matrigel Membrane Matrix (CB40230) (Thermo Fisher
Scientific, Waltham, MA, USA) coated plates with EB medium plus 16.7 nM of Noggin
and 10 µM of SB43152. On days 6 through 12, media was replaced with neural
progenitor medium [Gibco Neurobasal Medium (21103049)(Thermo Fisher Scientific,
Waltham, MA, USA), GlutaMax, Nonessential amino acids, Cytiva HyClone™
Penicillin Streptomycin Solution (SV30010)(Cytiva, Marlborough, MA, USA), Gibco™
N-2 Supplement (17502048) (Thermo Fisher Scientific, Waltham, MA, USA), 20 ng/ml
bFGF (233-FB-025) (R&D systems, Minneapolis, MN, USA)] at the volume of 2 mL per
well and changed every day. Upon seeing rosette formation at approximately day 11 or
12, cells were passaged into flasks coated with Poly-L-Ornithine (P4957-50ML) (Neta
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Scientific, Hainesport, NJ, USA) and Laminin (L2020-1M Scientific, Hainesport, NJ,
USA) (PLO/lam).
Culturing neural stem cells
Wildtype and Mutant NSCs differentiated from the original two populations of
CDKl5 Man0855-01 iPSCs were grown on PLO/Lamin (Neta Scientific, Hainesport, NJ,
USA) coated plates. Cells were passaged at 100% confluency at a density of 50,000100,000 cells/cm2. Media was changed the day after passaging and then every other day
(see Appendix A Table 1 for media components). A total of three wells each of wildtype
and mutant skewed NSCs were grown to approximately 100% confluency prior to cell
lysis and preparation for amplicon sequencing.
Cell lysis, RNA extraction, and cDNA synthesis in iPSCs and NSCs
Both Man0855-01 iPSCs and differentiated NSCs grown to approximately 100%
confluency in a 6 well plate was lysed using Tri Reagent (R2073)(Zymo Research,
Irvine, CA, USA) and stored at -80℃ until RNA extraction. RNA was first isolated from
cell lysates using Tri reagent chloroform extraction. Chloroform was added to the cell
lysates (at a volume of 1/5 of the total volume of Tri reagent). Lysates and chloroform
were mixed via inversion for 15 seconds and then left at room temperature for 2 to 5
minutes and then spun for at a max of 12000xG for 5 minutes in order to see phase
separation. RNA was then isolated by pipetting from the aqueous phase. To eliminate
genomic contamination, isolated RNA from the aqueous phase was further processed
with the Direct-zol RNA Miniprep Plus kit (R2073) (Zymo Research, Irvine, CA, USA)
according to the manufacturer’s instructions, with a 15-minute DNase1 treatment. Whole
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RNA was eluted with 30 ul of RNase/DNase free water. Following RNA extraction,
approximately 1 ug of RNA of each sample was reverse transcribed using the RevertAid
First Strand cDNA Synthesis Kit (K1622) (Thermofisher Scientific, Waltham, MA,
USA) according to the manufacturer’s instructions.
Exon spanning PCR of cDNA samples
For each sample, 2 ng of cDNA was used in a PCR reaction with a set of primers
that spanned exon 11 and 12 of CDKL5 (hsCDKL5pD471fsAS-F 5’-3’
GCCACTCATTCATGGAAAGC & hsCDKL5pD471fsAS-R 5’-3’
GTACTGGGCTCCGCAATTT) and Phusion High-Fidelity PCR Mastermix (M0531S)
(New England Biolabs, Ipswich, MA, USA). The thermal cycle program had a 10 min
initial denature at 98 °C, followed by 30 cycles of 10s at 98 °C to denature, 30s at 60 °C
to anneal, and 45s at 72 °C for extension. The final extension lasted for 10 min at 72 °C.
20 ul of the PCR product was run on a 1% agarose gel until 1 kb bands could be
separated for easy extraction without contamination from neighboring bands. 1kb Nested
PCR bands were then extracted from the agarose gel and purified using the Zymoclean
Gel DNA recovery kit (11-301C) Zymo Research, Irvine, CA, USA). DNA was eluted
with 12 ul of DNase/RNase free water to be used in a barcode PCR reaction.
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Barcode PCR and sequencing
Approximately 10 ng of purified DNA was used in a second PCR reaction with
barcoded forward and reverse primers and Phusion High-Fidelity PCR Master Mix with
HF Buffer (M0531S) (New England Biolabs, Ipswich, MA, USA). The thermal cycle
program had a 30s initial denature at 98 °C, followed by 35 cycles of 10s at 98 °C to
denature, 30s at 60 °C to anneal, and 45s at 72 °C for extension. The final extension
lasted for 10 min at 72 °C. Each forward primer had a 5 bp unique sequence to
differentiate between samples during multiplexing (Halmai et al. 2020). Amplicons from
this reaction were run on a 2% agarose gel. Then, 100 bp bands were extracted and
purified using the ZymoClean Gel DNA recovery kit as described above. Barcoded
amplicons were sequenced at the Massachusetts General Hospital Center for
Computational and Integrative Biology (MGH DNA core) on an Illumina MiSeq. The
resulting FASTQ files were downloaded from the MGH DNA Core website.
Analysis of amplicon sequencing results
FASTQ files from sequenced NSC and iPSC amplicons were processed with
Flash2 (Fast Length Adjustment of SHort reads)
(https://github.com/dstreett/FLASH2/blob/master/flash2.c) (flash2 -M 260 --interleavedinput file.fastq -o filename) in order to merge paired-in reads. Next, reads were processed
using FASTX Barcode splitter
(http://hannonlab.cshl.edu/fastx_toolkit/commandline.html#fastx_barcode_splitter_usage
)(cat filename.extendedFrags.fastq | fastx_barcode_splitter.pl \ --bcfile bol.txt --bol -mismatches 1 \ --prefix filename_bol \ --suffix ".txt") (cat filename_bolunmatched.txt |
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fastx_barcode_splitter.pl \ --bcfile eol.txt --eol --mismatches 1 \ --prefix filename_eol \ -suffix ".txt"), which splits fastq files into smaller files based on barcode identification.
Files identified as the beginning of sequence and files that are identified as end of
sequence are then concatenated (cat filename_bol.txt filename_eol.txt > filename.fq). The
percent of mutant and healthy CDKL5 reads is then determined using the grep function.
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Figure 3: Data Analysis Pipeline for Sequenced NSC and iPSC Amplicons - Flash2
was used to merge paired-in reads of NSC and iPSC amplicons. Then reads were processed using
FASTX Barcode splitter in order to split FASTQ files into smaller files based on barcode
sequence. Next, reads were processed using FASTX Barcode Splitter. Beginning of Sequence
(BOL) and End of Sequence (EOL) identified files are then concatenated into one file. Finally,
the grep function is used to find the count of healthy and mutant CDKL5 reads.

Quantitative PCR of cell pluripotency and neuronal markers in NSCs and iPSCs
cDNA from three biological replicates each of mutant and wildtype NSCs and
iPSCs, was reversed transcribed from whole mRNA from prior amplicon sequencing
experiments using RevertAid First Strand cDNA Synthesis Kit (K1622) (Thermofisher
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Scientific, Waltham, MA, USA). Using 20 ng of cDNA for each condition, quantitative
PCR on a StepOnePlus Real-Time PCR System (4376600)(Thermofisher Scientific,
Waltham, MA, USA) was set up with primers for the pluripotency markers OCT4 and
SOX2, the neuronal markers PAX6 and ASCL1 (OCT4 F:
CCCACACTGCAGCAGATCA, OCT4 R: CACACTCGGACCACATCCTT; SOX2 F:
GCCGAGTGGAAACTTTTGTCG, SOX2 R: GCAGCGTGTACTTATCCTTCTT;
PAX6 F: CTGAGGAATCAGAGAAGACAGGC,
PAX6 R: ATGGAGCCAGATGTGAAGGAGG; ASCL1 F:
CAAGAGAGCGCAGCCTTA,
ASCL1 R: GCAAAAGTCAGTGAACG) for detection with PowerUp SYBR Green
Master Mix (A25777)(Thermo Fisher Scientific, Waltham, MA, USA). Each biological
replicate was processed with three technical replicates per condition. Relative expression
of these genes was normalized to a GAPDH control (Forward 5’AATCCCATCACCATCTTCCA Reverse 5’- CTCCATGGTGGTGAAGACG) and delta
CT was calculated. Significant differences between cell types were assessed using an
ANOVA and Tukey’s posthoc (GraphPad Prism).
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Results

Refined sequencing preparation methods reveals differentiation does not correct skewed
CDKl5 expression
The mutant skewed iPSCs showed 7.51% wildtype allele reads and differentiation
of these cells into NSCs resulted in wildtype reads being reduced to 0.44% of reads
(Figure 1). Therefore, allelic expression in wildtype and mutant skewed NSCs was
evaluated to determine whether differentiation was the cause of this reduction.
CDKL5 patient iPSCs and NSCs were evaluated to confirm cell differentiation state. This
was evaluated with imaging (Figure 4) and quantitative PCR of pluripotency and
neuronal markers (Figure 5). Figure 4 shows iPSC and NSC populations that were
representative of the ones used for amplicon sequencing. CDKL5 iPSC colonies from
both wildtype and mutant skewed populations had iPSC-like morphology. Cells grew in
even round colonies with refractive edges. Prior to amplicon sequencing, some colonies
did exhibit signs of differentiation like irregular edges and these sections of the plate
were manually removed to reduce the chance including differentiating cells. NSCs were
larger cells compared to iPSCs with neuronal-like projections that grew in close network
with other NSCs. There was no discernible difference in morphology between wildtype
or mutant expressing populations in either the iPSCs or NSCs.
Quantitative PCR was then used to access the same cell identity markers in all
cells. OCT4 and SOX2 were used as markers of pluripotency. OCT4 is expected to be
enriched only in iPSCs because it is involved in maintaining stem cell pluripotency
(Takahashi and Yamanaka 2006). SOX2, on the other hand, was expected to be enriched
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in both iPSCs and NSCs because it maintains pluripotency as well as NSC self-renewal
(Takahashi and Yamanaka 2006; Pagin et al. 2021). PAX6, which is found in the central
nervous system (CNS) (Mo and Zecevic 2008) and ASCL1 were used as markers of
neural differentiation (Narayanan et al. 2019). These two markers were expected to be
only enriched in NSCs.

Figure 4: Representative Images of Wildtype and Mutant Skewed CDKL5 iPSCs and NSCs
Images shown show the typical morphology of cells prior to amplicon sequencing and quantitative PCR. a.)
Mutant skewed iPSC colony passage 15 at 5x magnification. b.) Wildtype skewed iPSC colony passage 8
at 5x magnification. c.) Mutant skewed NSCs at 10x magnification. d.) Wildtype skewed NSCs at 10x.
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The quantitative PCR analysis of the cell type indicators revealed elevated OCT4
and SOX2 in mutant and wildtype CDKL5 iPSCs (Figure 4). A Tukey’s posthoc revealed
significant differences between mutant skewed iPSCs and both NSCs for OCT4
expression (F (3, 29) = 11.91, p = 0.0039). For SOX2 expression, the significant
difference between cell types was seen between mutant iPSCs and mutant NSCs (F (3,
29) = 11.08, p = 0.0048). However, mutant NSCS had low relative expression of all
markers even in markers that were enriched in wildtype NSCs. For PAX6, there were
significant differences between wildtype NSC and wildtype iPSC expression and between
mutant iPSC and wildtype NSC (F (3, 29) = 6.243, p = 0.0217). In ASCL1 there were
significant differences between wildtype iPSCs and wildtype NSCs, between mutant
iPSCs and wildtype NSCs, and between wildtype and mutant NSCs (F (3, 30) = 30.22, p
= 0.002). In both PAX6 and ASCL1, relative expression was high in wildtype NSCs but
low in all other cell types, including mutant NSCs, which had low expression of all cell
markers.
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Figure 5: Relative Expression of Pluripotency and Neuronal Markers in Wildtype and
Mutant iPSCs and NSCs Three biological replicates (wells) of CDKL5 patient iPSCs and NSCs
(wiPSCs: wildtype skewed iPSCs, miPSCs: mutant skewed iPSCs, wNSC: wildtype skewed
NSCs, mNSC: mutant skewed NSCs) were accessed for expression of OCT4, SOX2, PAX6, and
ASCL1. qPCR data was normalized to GAPDH expression. An ANOVA with a Tukey’s multiple
comparison’s test was used to determine significant differences in gene expression between
groups. a.) Relative expression of pluripotency markers OCT4 (F (3, 29) = 11.91, p = 0.0039) and
SOX2 (F (3, 29) = 11.08, p = 0.0048). b.) Relative expression of neuronal markers PAX6 (F (3,
29) = 6.243, p = 0.0217) and ASCL1 (F (3, 30) = 30.22, p = 0.002).

In order to assess whether low level expression of the silenced allele was the
result of the naive state of iPSCs, expression of CDKL5 in NSC was evaluated again with
a more rigorous amplicon preparation approach. In initial amplicon sequencing
experiments (Figure 1), cDNA was directly barcoded for sequencing. If genomic DNA
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was not eliminated during RNA extraction, it is possible that it could act as a false flag
for allele expression. The new amplicon preparation approach removed the risk of
genomic contamination first by including a preliminary chloroform trizol RNA extraction
to pre-isolate RNA prior to using an RNA purification kit with a DNase treatment. Then,
after cDNA synthesis, cDNA was amplified using exon 11 and 12 spanning primers for
the CDKL5 gene and size selected on an agarose gel. This was intended to eliminate any
amplicons produced directly from genomic DNA by skipping over introns. The product
from this size selection was then barcoded and sequenced.
Figure 6 shows the average expression of mutant and wildtype CDKL5 in NSCs
differentiated from both wildtype and mutant skewed iPSCs. Differentiation of CDKL5
iPSCs does not yield cell populations that are clonal. Wildtype skewed iPSC derived
NSCs still express between 6.3 and 7.84% (average: 7.13%; standard deviation: 0.78) of
their reads as the “silenced” mutant allele between biological replicates. Similar results
are seen in NSCs differentiated from mutant skewed iPSCs. Mutant skewed NSC
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biological replicates still express between 2.63 and 12.07% of their CDKL5 reads as the
silenced wildtype CDKL5 allele (average: 7.4; standard deviation: 4.72).

Figure 6: The Average Percentage of Mutant and Wildtype CDKL5 Amplicon Read in
Man0855-01 Neuronal Stem Cells. Samples were amplicon sequenced from neuronal stem cells
(NSCs) that were differentiated from both the wildtype skewed and mutant skewed iPSCs. Error
bars represent the standard deviation. Magenta (right bar) is mutant allele CDKL5 expression.
Teal (left bar) is the wildtype cDKL5 allele. a.) The percentage of mutant to wildtype CDKL5
amplicon reads in NSCs differentiated from wildtype skewed iPSCs. b.) The percentage of
mutant to wildtype CDKL5 amplicon reads in NSCs differentiated from mutant skewed iPSCs.

Amplicon sequencing of clonally selected Man0855-01 iPSCs
To determine whether a mixed population was the cause of low-level expression
of the silenced allele, single cells from both the wildtype skewed and mutant skewed
iPSCs were clonally expanded. Each selected colony was expanded into three wells of a
six well plate and then processed for amplicon sequencing using the same methods as
previously described for NSCs (See Table 2). All colonies had clonal expression. Seven
clones from wildtype skewed iPSCs were amplicon sequenced for wildtype and mutant
CDKL5 allele expression (Figure 7). All reads in colonies C, B, F, and A are wildtype
CDKL5 allele. Clones A, C*, and B* have a small percentage of mutant allele reads
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(1.15%, 0.01%, 0.01%, respectively) but all these values are below the expected error for
the Illumina MiSeq (median of 0.473 +-0.938) (Stoler and Nekrutenko 2021). In the
single colony selected from the mutant skewed iPSCs there is also a small amount
(0.37%) of reported wildtype reads but this number is below MiSeq’s expected error.
Table 2 - Passage Number and Parent Population of Selected iPSC Clones
Clone Name

Original Population

Passage Number

B

Mutant Skewed

20

C

Wildtype Skewed

14

A

Wildtype Skewed

13

B*

Wildtype Skewed

14

F

Wildtype Skewed

14

A

Wildtype Skewed

15

C*

Wildtype Skewed

13
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Figure 7: The average percentage of Mutant and Wildtype CDKL5 Amplicon
Reads from Colonies clonally selected from both Wildtype Skewed and Mutant
Skewed Man0855-01 human iPSCs (hiPSCs). Samples were prepared according to
the methods with nested PCR included. Each average represents two to three replicates.
Each replicate represents one well of a six well plate that a clonally selected colony was
expanded into. Error bars represent the standard deviation. a. Average percentage of
wildtype and mutant CDKL5 reads from 7 colonies selected from wildtype skewed
CDKL5 patient iPSCs. b. Average percentage of wildtype and mutant CDKL5 reads
from one colony selected from mutant skewed CDKL5 patient iPSCs.
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Discussion

The goal of aim 1 was to evaluate the state of XCI in a CDKL5 patient iPSC and
NSC. Specifically, after initial sequencing revealed that populations of cells that were
expected to have monoallelic CDKL5 expression had low level expression of the
“silenced” allele the cause of this unexpected expression was evaluated with two
hypotheses. One hypothesis was that incomplete XCI was occurring in the iPSCs because
of their naive state of development. The other was that a mixed population of cells was
present.
In order to evaluate whether it was the cell’s state of development that was
causing “silenced” allele expression iPSCs were differentiated into NSCs and then
sequenced for CDKL5 allele expression. To determine whether cell state could affect the
silencing of CDKL5 on the Xi, morphology and the relative expression of cell
differentiation stage markers helped confirm cell identity. All cells had the morphology
expected. Quantitative PCR looked at the differences in expression of OCT4, SOX2,
PAX6, and ASCL1 between all cell populations. These cell state markers were used as
indicators of differentiation state. A balance of OCT4 and SOX2 levels are necessary to
maintain a pluripotent state. PAX6 and ASCL1 indicate neuronal differentiation. There is
clear enrichment of OCT4 in both populations of iPSCs compared to NSCs. SOX2 is
enriched in both iPSC populations, as expected, but was also found in wildtype NSCs.
This is an expected result because SOX2 plays a secondary role in the regulation of
neuronal differentiation (Zhang and Cui 2014). The lack of SOX2 in mutant NSCs is
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unexpected but this low expression is seen in all other markers, perhaps signaling a
difference in health or differentiation in these cells. Setting aside this aberration in the
mutant NSCs momentarily, the expression of the neuronal markers PAX6 and ASCL1 in
wildtype NSCs and the near absence of these markers in iPSCs supports that the wildtype
NSCs were more differentiated down a neuronal pathway compared to the iPSCs. This
corresponds well with the differences in morphology seen. The data also show expression
differences between mutant and wildtype populations. This could be the result of a health
difference in these populations or how they were processed, but it is unlikely processing
of these samples is the cause because GAPDH (control) expression was similar in all
populations. A likely explanation for discrepancy between wildtype and mutant iPSCs for
pluripotency markers is known variation in these markers in the literature. iPSCs can
have variances in the level of pluripotency markers and still pass all other criteria for
pluripotency (Vitale et al. 2012).
Results of amplicon sequencing in NSCs did not reveal any significant loss in
silenced allele expression (although mutant NSCs have a large standard deviation of
expression calling again to question the health and differentiation level of these cells). In
the original data, wildtype skewed iPSCs expressed 8.27% of their reads as the mutant
allele and mutant skewed iPSCs had 7.51% wildtype reads. Based on the read error for
Illumina MiSeq and the standard deviation of the NSC data, no apparent change in allele
silencing appears to be occurring. Overall, this data does not support an incomplete XCI
hypothesis.
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The mixed population hypothesis was evaluated by doing a single cell clonal
expansion of wildtype and mutant skewed iPSCs and sequencing for allele expression.
All colonies sequenced either have 0% silence allele expression or allele expression that
is so low it is below the expected error for MiSeq. For this reason, all eight colonies
observed are declared as clonal. These results clearly indicate that the mixed population
model is most likely correct. If it was not and incomplete XCI was occurring, one would
still expect low-level expression of silenced CDKL5 in these colonies.
This clonal result has important ramifications both for the Man0855-01 cells
being considered and for the use of iPSCs for X-linked studies in general. The clonality
in the Man0855-01 iPSCs bodes well for their use as a model to study XCI reactivation.
This is because clonality with respect to X-linked expression is a requirement for
accurately observing the results of reactivation experiments. The other insight is that
these methods of differentiation and clonal selection can be used as an assay to determine
XCI state in other uncharacterized iPSCs.
In order to move on with these cells as models for targeted reactivation in patient
CDKL5 models a few limitations of this study might be considered. The Tukey’s posthoc
in quantitative PCR did not find significant differences between all iPSCs compared to all
NSCs as expected. The relative expression in mutant skewed NSCs was overall low in all
cell markers, even the ones where it was expected to be enriched (ASCL1). It cannot be
confirmed with the current data that these cells were NSCs. Ideally, qPCR assays would
be repeated to confirm whether this unexpected result persists as there is a possibility
either the health of these cells or their diseased status could have affected expression. To
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confirm NSC identity, immunocytochemistry could be performed using Nestin, Sox2,
MSI-1, and BMI-1 specific antibodies (Vinci et al. 2016). However, given that there was
a significant difference between some iPSCs to NSCs in some of the cell markers and the
morphology between the iPSCs and NSCs are completely different, these limitations
likely do not change the most likely conclusion of this study. The differentiation stages
between the iPSCs and NSCs are clearly different based on morphology. These
differences in morphology did not correspond with a change in relative silenced CDKL5
allele expression. This contradicts the naive iPSC state hypothesis being the cause of
leaky CDKL5 allele expression in the original set of iPSCs.
Despite some of these limitations, the data suggests some broader conclusions
about the state of Man0855-01 iPSCs and NSCs and how they might be used for
reactivation experiments. Because the evidence supports a mixed population and does not
support that there is unstable or incomplete XCI, these cells are well-suited for targeted
XCI escape experiments because they can be made into isogenic populations after clonal
selection. This result matches up with several prior studies on the stability of XCI in Rett
syndrome like disorders including CDD in which it was possible to create clonal
populations because XCI was stable (reviewed in Cheung et al. 2012; Ananiev et al.
2011; Amenduni et al. 2011; Pomp et al. 2011).
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AIM 2: EXPLORING BIOINFORMATICS METHODS TO ANALYZE HISTONE
MODIFICATIONS ON ESCAPE AND SILENCED GENES ON Xi
Introduction

X chromosome inactivation (XCI) allows for dosage compensation of X-linked
gene expression between males and females (Lyon 1962). During early embryogenesis,
the long non-coding RNA Xist initiates XCI by coating the pre-inactivated X. This
facilitates the recruitment of factors that induce silencing in a multistep process. Early on,
the chromosome loses RNA polymerase 2 and activating histone marks (Chaumeil et al.
2002; 2006). Concurrently, Polycomb Repressive Complexes (PRC) 1 and 2 catalyze the
deposition of the repressive marks H2AK119ub1 and H3K27me3, respectively (Plath et
al. 2004; Silva et al. 2003; Napoles et al. 2004). In the later phases of XCI, the histone
variant macroH2A replaces H2A and gene promoters become broadly hypermethylated
(reviewed in Escamilla-del-Arenal et al. 2011). These changes result in the formation of a
heterochromatic Barr body in which most genes are silenced.
Escape genes or escapees, genes that retain at least 10% of active X (Xa)
expression, comprise about 15 to 30% of genes on the inactive X (Xi) (Carrel and Willard
2005). Escape genes can be described and categorized by how consistently they escape
XCI across individuals and tissues and by their levels of expression. Approximately 10%
of X linked genes consistently escape XCI (Sauteraud et al. 2021). In contrast, up to 30%
of X-linked genes variably escape XCI depending on the individual or tissue type
(reviewed in Sauteraud et al. 2021; Carrel and Willard 2005; reviewed in Carrel and
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Brown 2017; Tukiainen et al. 2017; Garieri et al. 2018). To add to the complexity, the
level of “escape” (i.e expression) in escape genes can also vary (Carrel and Willard
2005). For example, expression levels of the escape gene FLJ39679 has been shown to
range from approximately 25% of Xa to over 75% of Xa expression (Carrel and Willard
2005).
Escape genes are epigenetically distinct from their silenced counterparts because
they resemble active genes on Xa (Balaton and Brown 2021; reviewed in Balaton and
Brown 2016). Escapees have increased levels of activating histone marks such as a
H3K4me2/3, H3K9ac, H3K27ac, H3K9me1 (reviewed in Balaton and Brown 2016; Qu
et al. 2015; Kucera et al. 2011; Sousa et al. 2019). They also lack repressive histone
marks like H3k27me3 and promoter methylation (reviewed in Fang 2019; Cotton et al.
2015). Hypomethylation in promoters reliably predicts escapee status in genes when it is
not possible to determine allelic expression via a skewed (clonal) XCI population and
SNPs (Cotton et al. 2015; Duncan et al. 2018). In contrast, silenced genes are often
enriched for repressive marks such as H3K9me3, H4K20me3, H3K27me3, and
macroH2A (reviewed in Balaton and Brown 2016; Qu et al. 2015; Kucera et al. 2011).
Their gene promoters are also typically hypermethylated. These patterns appear as the
generalized rule but vary from gene to gene. Several studies have suggested that normally
no single epigenetic feature except DNA hypomethylation accurately predicts XCI status.
Instead, a combination of epigenetic and genomic features is a more accurate predictor
(Balaton and Brown 2021; Sousa et al. 2019).
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The therapeutic role of escape
Due to random XCI, half of cells in female tissues express the maternal X and the
other half express the paternal X. If one of the alleles on an X gene is defective, this
resulting mosaicism can lead to an X-linked disorder that is characterized by pseudohaplosufficiency. Inducing XCI escape might alleviate this pseudo-haploinsuffiency by
restoring healthy allele expression levels. Natural XCI escape is likely what allows
human females with an OFD1 mutation to live until their 40s while female mice, which
do not have escape in OFD1, die early like OFD1 mutant male humans and mice.
Females are also hypothesized to have reduced cancer rates compared to males because
of XCI escape in tumor suppressor genes (Dunford et al. 2017).
Understanding the epigenetic features in natural escape genes versus silenced
could benefit this goal of selective silenced gene reactivation. As described earlier, the
identity of epigenetic markers in different XCI states is well-defined. Research, however,
is still continuing on the levels of these markers. This is potentially valuable because
enrichment of features is likely coupled with expression (Karlić et al. 2010). Moreover,
there likely exists a threshold of epigenetic marker levels (either the loss silencing
markers or the gain of activating ones) that would result in escape. This is potentially
useful to know when inducing artificial escape states. For this purpose, the goal of this
chapter is to introduce guidelines for the bioinformatic tools used to determine the
enrichment of epigenetic markers in known escape and silenced genes.
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General methods of X chromosome epigenetics analysis
The strategies for accessing epigenetic signatures on Xi can be broadly classified
as allele-specific analysis and relative analysis. In allele-specific analysis, reads from
ChIP or bisulfite sequencing experiment are phased to one of two parental haplotypes
based on where the read is a better match. This relies on the known presence of
heterozygous single nucleotide polymorphisms and other mutations on both X
chromosomes. The typical output of this method will depict allele-specific alignments
either visually (such as a wiggle track) or as a count of alignments for every heterozygous
SNP. Given enough reads align for peaks to be called, one can then infer if an epigenetic
mark is enriched in an allele-specific manner. The second approach, relative analysis,
compares quantitative differences in epigenetic markers (often between females and
males) without sorting and dividing reads based on the haplotype. To illustrate, X
chromosome gene promoters in males are usually hypomethylated because their X
chromosome is active. If that same gene is silenced in the female Xi, that gene is going to
be hypermethylated on Xi and hypomethylated on Xa. A measurement of the total
enrichment of methylation at that gene on both female X's and the male X will show
more total methylation in the female. One can then identify a likely escape gene based on
whether its methylation level is an intermediate of these two extremes. This is because
the escape gene will be partially methylated on Xi and hypomethylated on Xa (Balaton
and Brown 2021).
Relative analysis is also possible without male samples. For example, higher
overall promoter methylation in silenced genes vs escapees is enough to distinguish
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escape status without expression analysis (Cotton et al. 2015). Within a single female
sample, high levels of H3K36me3 (associated with active transcription) compared to
H3K27me3 (a silencing mark) can also be used to identify biallelic autosomal genes and
might also be useful for identifying escape status (Balaton and Brown 2021).
Data requirements in allele-specific and relative analysis
Allele-specific analysis allows for more direct quantification of epigenetic
markers on silenced and escape genes, but its stringent data requirements limit the pool of
available datasets. Many allele-specific analysis tools require both the genome of the
sample being tested and the haplotype origin of all heterozygous SNPs. This requires
sequencing of parent and child trios like the GM12878 (child)-GM12891-GM12892 trio
from the 1000 Genomes Project (reviewed in Durbin et al. 2010). The cell population
being tested also has to be clonal with respect to Xi, so that Xi will always map to one
parental X in all cells. Without clonality, haplotype-specific alignments to each parental
X will not clearly correspond to Xi or Xa. Natural XCI usually results in mosiac
populations that would not be useful for allele-specific analysis because Xi is going to be
represented in both parental chromosomes (at a 50/50 ratio). Therefore, appropriate data
sets for this type of analysis should either come from clonal expansion or single-cell
epigenomics.
Relative analysis does not require as stringent data requirements. Samples do not
need to be clonal nor do they need to be a part of a sequenced parent child trio. Generally,
relative analysis relies on aligning all epigenetic reads from a sequencing experiment
without splitting based on haplotype. Further requirements for relative analysis depend on
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the type of relative analysis. The first type of relative analysis, which requires both male
and female samples, compares the total enrichment of epigenetic marks between the
sexes (Balaton and Brown 2021). The task is simpler in relative analysis comparing
H3K27me3 and H3K36me3 enrichment because the analysis is on one sample from a
single individual (Nag et al. 2013).
Despite the less stringent data requirements of relative analysis, allele specific
analysis was chosen for this study because it looks precisely at the enrichment of
epigenetic features on Xi in a haplotype specific matter. For this reason, the next section
focuses on allele-specific analysis in ChIP-seq data.
Assessing ChIP-seq data quality
Allele-specific ChIP-seq analysis should first rely on best practices for assessing
ChIP-seq quality. The goal of quality assessment metrics in ChIP-seq is to assess both
the quality of the immunoprecipitation experiment and sequencing. The first concern is
having sufficient sequencing depth to have statistical significance (Bailey et al. 2013;
Jung et al. 2014). Depth, or coverage, refers to the number of times sequenced
nucleotides cover the genome being sequenced. It other words, it is the number of times a
section of nucleotides has been read. Mathematically it is the total number of bases
sequenced divided by the size of the genome. So, when the question of coverage is
considered what really is being considered is how many reads should be in the dataset
such that as many enrichment peaks can be detected against a background input as
possible.
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The number of reads recommended for ChIP-seq generally depends on both the
size of the genome, the number of places the chromatin mark can localize, as well as the
size of the binding site. For human data, chromatin modifications which tend to bind in
narrower regions like (H3K4me2, H3K4me3, and H3K9ac) require about 20 million
reads (Landt et al. 2012; Bailey et al. 2013). However, most chromatin binds over a wide
area, so read counts up to 60 million might be required (Chen et al. 2012; Bailey et al.
2013). To come up with an overall depth recommendation for all human ChIP-seq, Jung
and colleagues did a saturation analysis by assessing the number of reads required to
reach sufficient depth in a variety of histone modifications in human samples. They took
a read set containing 55 million reads and looked at the enrichment regions revealed by a
dataset that large. Then they took a subset of those reads and gradually increased the read
number in the subset to observe the recovery of known enrichment regions in the larger
data set. The defined sufficient depth as the depth at which adding 1 million more reads
will not reveals less than 1% more of the total enriched regions. In other words, the
amount of return for adding more reads was so low to not necessarily justify deeper
sequencing costs. H3K4me3, H3K36me3, H3K27me3 ChIP-seq required 25, 25, and 40
million reads, respectively (Jung et al. 2014). Even at a total of 55 million reads there was
not sufficient depth for recovery gains to go below 1% in H3K9me3 (Jung et al. 2014).
They concluded that for most human ChIP-seq experiments 40 to 50 million reads for
most human chromatin is sufficient (Jung et al. 2014). Alongside the immunoprecipitated
sample it is normal to also sequence a subsample of chromatin that did not have
immunoprecipitated proteins. This input control serves the purpose of determining
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whether peaks of reads seen in ChIP-seq alignments are not the result of repetitive
elements. Control input should have higher read count than immunoprecipitated samples
(Bailey et al. 2013). Technical replicates can be combined if read counts are too low
(Bailey et al. 2013).
After selecting a sufficient depth for the ChIP-seq experiment, the resulting raw
reads can be analyzed for quality (Bailey et al. 2013) (Khetani 2019). FastQC is a
straightforward tool for this that works both with a command line or graphical user
interface (Bailey et al. 2013). Given a FASTQ file of reads, it outputs an HTML file of
several read quality figures, which will be flagged if there might be a cause for concern.
The “Basic Statistics Output” reveals a summary of the total sequences read, their length
and the percent of GC content. Unexpected GC content flagged by FastQC indicates that
the ChIP has enriched regions high in GC content compared to the rest of the genome or
that contamination from another species has occurred (i.e. bacteria). “Per Base Sequence
Quality” is a set of box and whisker plots that reveal the median and range of quality
scores at each position of the read (FastQC Tutorial & FAQ). A quality score represents
the chance that a base call is wrong. A Phred quality score of 10 corresponds to a 1 in 10
probability that is a base is called incorrectly (Q(phred) = -10 log P where P is the
probability of an error). The Phred quality score is generated by the sequencer itself and
formatted in the FASTQ file alongside reads (Quality Score 2018). It then gets decoded
into user-friendly information by FastQC. A desirable result for “Per Base Sequence
Quality” is that all box and whisker plots have a high median quality score with little
range for the entire length of the read (FASTQC Tutorial & FAQ).

60
FastQC’s per sequence quality score looks at the distribution of FastQC scores
over all reads (FastQC Tutorial and FAQ). Ideally, one should see a sharp peak around a
high Q score because wrong base calls could be mistaken for a SNP. The “Per tile
sequence quality” heatmap can be used to determine if there were certain areas of the
flow cell that consistently misread certain base positions (FastQC Tutorial and FAQ).
Any reads with quality score below 20 (less than 99% accurate) should be filtered
from the total data set (“Phred Scaled Quality Scores”). Trimming can be performed if
there is sharp drop off of read quality at higher read lengths (Mohsen et al. 2019). Once
necessary cleanup is done, reads can be mapped with an alignment tool such as Bowtie,
BWA, or SOAP (Bailey et al. 2013). This is done because the expected percentage of
uniquely mapped reads in humans should be above 70%. If the percentage falls below
50% this could indicate that read lengths are not long enough, a sequencer issue, or that
there was too much PCR amplification when the DNA was prepared (Bailey, 2014). To
determine this, one can either set the alignment algorithm to only report uniquely mapped
reads or filter an alignment file to determine uniquely mapped reads or filter already
aligned files using a tool like Samtools (Bailey, 2013; Li et al. 2009).
With the aligned reads, another quality check is to generate a fingerprint plot of
the data (Diaz et al. 2012; plotFingerprint). A good ChIP experiment will contain reads
that are mostly the result of bindings from immunoprecipitation and as little background
DNA as possible (Diaz et al. 2012; plotFingerprint). Deeptools plotFingerprint takes a
sorted and indexed BAM file (a compressed version of a SAM file) from the
immunoprecipitated reads and the input control and produces a visual of how well signal

61
stands out from background. The plot shows the cumulative read coverages for each
BAM file. To produce it, overlapping reads were sorted into bins (windows) based on
where they align. This produces a count of reads that overlap each bin. The final output
is a figure of the cumulative counts of reads that cover each bin (read coverage) sorted by
rank. Input reads should be evenly distributed across the genome because they should
represent unenriched sheered DNA. Ideally, this should look like a diagonal line of
uniformly distributed reads. The immunoprecipitated reads should have an uneven
distribution in which some bins (genomic regions) have higher counts of reads than
others. The narrower the expected peak for a histone modification the more obvious this
will be because reads will be enriched over smaller regions. PlotFingerprint is most clear
when used to assess the quality of ChIP-seq in markers that have rather tight and defined
peaks like transcription factors binding and H3K4me3, H3K4me2, or and H3K9ac marks.
Broader marks that do not enrich for a narrow region might not be easily distinguished in
the fingerprint plot (because reads will cover more bins). It should be kept in mind,
therefore, that depending on the histone target this assay does not diagnose that the ChIPseq enrichment failed (plotFingerprint; Diaz et al. 2012).
Allele-specific analysis
AlleleSeq is a pipeline designed to determine the differences in expression or
binding between maternal and maternal alleles. The first phase of this pipeline is the
creation of a diploid personalized genome that has genome sequence variances (such as
SNPs or structural variants) that can be used to distinguish between chromosomes. This is
done by using vcf2diploid to combine phased variation data stored in a VCF file with a
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reference genome. Vcf2diploid represents the original reference genome as an array of
nucleotides where every cell of the array represents a base. Cells of this array are then
modified so that it matches genomic variations. The output of vcf2diploid is a set of
FASTA sequences representing a phased genome with Map files, which map nucleotide
positions between maternal and paternal chromosomes and the reference. Crossmap tool
is used to map the locations of genes known on the reference genome to the new
personalized diploid genome using chain files (Zhao et al. 2014).
In the second phase of AlleleSeq, allele specific events (either allele specific
expression or binding) are diagnosed when a significant number of reads that map in a
region map preferably to one of the parental alleles. This preferential mapping to one
allele or the other is based on the heterozygous genome sequence variances that exist
between alleles. Reads are mapped separately to the maternal and paternal haplotypes
using Bowtie with parameters set so that a given read maps to only one location with as
few mismatches as possible (and at most, 2). A mapping location for the read of one the
two haplotypes is chosen based on which alignment is best (i.e., which alignment most
faithfully matches the reference sequence). Mappings that tie in quality are assigned at
random to one haplotype. This process results in a read count of the number of
alignments for every heterozygous SNP position in the genome. Any SNP positions that
might have copy number variants (CNV) are excluded. CNVs are diagnosed prior to
using allele-seq using read depth analysis of genomic DNA that has been sequenced in a
separate experiment. If the read depth in a 1kb area around a SNP is less than 1 or
greater than 3 it is declared a CNV. Potential CNV-containing reads are excluded because
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it is ambiguous whether such a read will be enriched because of immunoprecipitation or
because there are multiple copies of that sequence in the genome.
For every SNP location, AlleleSeq outputs a table that shows the numbers of As,
Ts, Cs, and Gs that map at that location with the bases that exist in the maternal and
paternal chromosome. With the counts per base is a binomial P-value that assumes that
there is a 50/50 probability of sampling each allele (a 50/50 probability assumes that
there are no allele specific events at that location). Allele specific events are declared via
a binomial test after corrections for multiple hypothesis testing. A false discovery rate
(FDR) is calculated by creating a computational simulation. For every SNP location, a
mapped read is assigned to either allele. They use a P-value threshold from a binomial
test, to estimate the number of false positive allele specific events that would be called.
The FDR is this resulting number of false positives divided by the total number of allele
specific events that occurred. The FDR Rowzosky et al. selected was less than 10%, a
relaxed threshold in order not to exclude as many specific events. Making the threshold
stricter and more accurate means that fewer allele specific events would be observed
(Rowzosky et al. 2011).
The goal of this chapter is to illustrate use of these described tools for assessing
ChIP-seq data in an allele specific manner on the human X chromosome. This study was
performed using public ChIP-seq data produced by Nag and colleagues from the
Gimmelbrant lab at Harvard (Nag et al. 2013). Other datasets from Encyclopedia of DNA
Elements (ENCODE) were used to illustrate sections in which the Nag dataset was not
suitable. The primary intent of this section is to first illustrate how datasets were chosen
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and to describe how all preprocessing and analysis steps were performed. Resulting data
outputs are then used to discuss how they compare with the expected “ideal” result with
notes on ways the starting input could be improved.
Methods

Notes on installations and conventions used
The tools described in methods were installed on a Linux Ubuntu 20.04.4 LTS
system. Most of the commands shown should be applicable to other Linux or Unix
systems. Installation details have been left out because that depends on operating
systems. With this in mind, the command line statements shown in this section assume
that a tool is already installed and, if on Linux or Unix, that the directory where the
software was installed is added to the users PATH variable in their bashrc file (Table 3).
This step informs the terminal where the executable file of the program is stored.
Otherwise, the terminal will print a warning message stating “Command [X] not found”.
For clarity, code snippets are presented as a table in this section alongside text to both
enhance the readability of code and make it easier to replicate this work (Table 4).
Readers may read the text straight through without the code snippets for a general
overview of the analysis.

65
Table 3 - Steps to Edit Bashrc
Table 3 - Steps to Edit Bashrc
# After installing a tool, go into the tools directory and find the directory that contains its
executable file(s). Often, the directory is called “bin”.
# print working directory and copy it
$pwd
→ directory/path/to/tool/executables
# open bashrc file and scroll to the bottom to edit
$nano ~/.bashrc
# add this to the bottom of .bashrc with only a space between “export and PATH”
(within bashrc)
export PATH=directory/path/to/tool:$PATH
# update current shell environment to use new PATH
$source ~/.bashrc

Table 4 - Code Formatting
Table 4 -Code Formatting
$command with dollar sign

→ output
# comment
(within file X)
…
Code

Meaning
Linux/Unix Command line statement. User
inputs the commands into the terminal
(with modifications). Do not enter the
“$”. “$” is included to signify the start of
a new command on the terminal.
Expected Output.
Explanatory comment. User does not input
this as a command.
Internal contents of a specific file.

Cell line selection
As variably escaping genes can be individual and tissue-specific (reviewed in
Balaton and Brown 2021) the first step was selecting a well-characterized female cell line
for analysis that has known escape genes. GM12878, a female lymphoblast cell line
immortalized using the Epstein Barr virus, was chosen for this reason. GM12878 is one

66
of the original cell lines in the 1000 genomes project an international project that studies
genetic variations between people and often within families (Reviewed in Durbin et al.
2010). This means its genomic variants and the variants of its parents are known. In
AlleleSeq’s debut, the phased variant data of GM12878 and the hg19 reference genome
were combined using VCFTools to build a phased genome assembly for NA12878
(Resources:1-Phased NA12878 Genome) (Rozowsky et al. 2011). This cell line is a good
model for studying escape genes because its escape genes have already been identified
using single-cell RNA sequencing (Katsir and Linial 2019) (Resources: 2- NA12878
Escape Genes).
ChIP-seq datasets used
Public domain data of H3K36me3 and H3K27me3 ChIP-seq was selected for
analysis because it is derived from clonal populations of GM12878 (Nag et al. 2013).
These GM12878 clonal populations were produced through single-cell sorting with
Fluorescence Activated Cell Sorting (FACs) after propidium iodine staining and then
expanded for 21 to 24 days (Nag et al. 2013). H3K36me3 (AB9050) and ABE44
(Abcam) antibodies were used for chromatin immunoprecipitation. SNPs over coding
regions in the immunoprecipitated DNA were then probed with Padlock probes. These
probes targeted 36,456 coding SNPs in GM12878. Data is available on the Sequence
Read Archive (SRA) Run Selector from NCBI under the accession number
PRJNA229064 (Resources: 3-Clonal GM1878 Datasets). Run SRR1063296 and
SRR1063300, which both represent sequenced H3K36me3 immunoprecipitated DNA in
the GM12878 DF2 clone and run SRR1063297 for H3K27me3 in the DF2 clone were
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downloaded by using the SRAtookit command interface fasterq-dump command (See
Resources: 4-SRA toolkit ￼). This produces a Fastq file of reads for each dataset(Table
5).
Table 5 - Download H3K36me3 datasets from Sequence Read Archive (SRA)
Table 5 - Download H3K36me3 datasets from Sequence Read Archive (SRA)
$fasterq-dump SRR1063296
$fasterq-dump SRR1063300
$fasterq-dump SRR1063297

To illustrate the use of fingerprint plots to access ChIP-seq quality two additional
resources were used because H3K36me3 and H3K27me3 typically do not produce clear
figures because they are broad histone marks. Transcription factor CTCF ChIP-seq data
was produced by the Michael Synder Lab at Stanford (Resources: 5-CTCF Data:).
H3K4me3 data was produced by the Berstein Lab at Harvard (Resources: 6-H3K4me3).
FastQC and filtering reads for quality
Quality of reads from the H3K36me3 SRR1063296 and SRR1063300 datasets
were first accessed using FastQC (Table 6) (Resources: 7-FastQC Tool). This produces a
HTML file and a zip file of read quality metric figures. Reads from both datasets were
then filtered for a Phred score quality of at least 20 using the fastq_quality_filter
commands from FASTX Toolkit (Resources: 8-FASTX Toolkit). Finally, in order to
have a dataset closer to 25 million reads, the filtered versions of the datasets were merge
into one FASTQ file(Table 6). This merged file was processed with FastQC again to look
at the new read count and any new changes in quality. H3K27me3 reads (SRR1063297)
were observed with FASTQC and filtered in the same manner. These latter data sets were
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used to illustrate the effectiveness of AlleleSeq and are not used again until the
“AlleleSeq” section of the methods.
Table 6 - FastQC and Quality Filtering
Table 6 -FastQC and Quality Filtering
$fastqc SRR1063296.fastq
$fastqc SRR1063300.fastq
$fastqc SRR1063297.fastq
# view the html files using google chrome
$google-chrome SRR106326_fastqc.html
$google-chrome SRR1063300_fastqc.html
$google-chrome SRR1063297_fastqc.html
# filter both datasets by read quality 20
$fastq_quality_filter -q 20 -Q33 -i infile -o filtered_infile
# Merge FASTQC Files together
$cat filtered_SRR1063300.fastq filtered_SRR1063296.fastq > merged_h3k36.fastq
# FastQC again to view read counts and other quality features again of the merged and filtered
read sets

Genome folder setup and alignment with Bowtie2
Reads were then aligned to the GM12878 genome from the Gerstein Lab
(Resources:1-Phased NA12878 Genome). The filename downloaded was
“NA12878_diploid_2012_dec16.zip”. This zip file was placed in a designated project
directory, unzipped, and renamed GenomeFolder. This folder contained FASTA (. fa)
files for all maternal and paternal chromosomes, Map files, and chain Files. Map files
(.map) store how a base position in the paternal FASTA file corresponds to its position in
the maternal and reference genomes. Chain files (. chain) can be used to relate gene
annotations from the reference genome to the phased genome. The genome was then
indexed with Bowtie2 using the bowtie2-build command (Table 7). Only the maternal
files were indexed because the initial alignments are only used to access the quality of the
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ChIP-seq data set without regards to haplotype. The H3K36me3 FASTQ file was then
aligned to the maternal chromosome using Bowtie2 with a local alignment because in the
previous steps the FASTQ files were not trimmed (Table 8). In order to do both Bowtie2
indexing and alignments for multiple chromosomes at once a shell scripting “for loop” is
shown in the code snippet example. Once alignments are finished, files were converted
from SAM format (Sequence Alignment Map) to BAM (the binary version of SAM
Format) in order to conserve disk space.
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Table 7 - Building Indices before Bowtie2 Alignments
Table 7 - Building Indices before Bowtie2 Alignments
$cd GenomeFolder
$ls
→ a large group of multiple copies of the following files, one for each chromosome
_NA12878.map
_NA12878_maternal.fa
_NA12878_paternal.fa
and
paternal.chain
maternal.chain
# to index just one chromosome file (for example, chromosome 9)
$bowtie2-build 9_NA12878_maternal.fa 9_
$ls *.bt2
→ 9_.rev.1.bt2 9_.rev.2.bt2 9_.1.bt2 9_.2.bt2 9_.3.bt2 and 9_.4.bt2
# to do this recursively for all maternal chromosome files in the directory
$indices=("1_" "2_" "3_" "4_" "5_" "6_" "7_" "8_" "9_" "10_" "11_" "12_" "13_" "14_" "15_"
"16_" "17_" "18_" "19_" "20_" "21_" "22_" "X_")

$for i in ${indices[@]}; do bowtie2-build $i*maternal.fa $i; done

Table 8 - Bowtie2 Alignment
Table 8 - Bowtie2 Alignment
# to do a single alignment, to do a global alignment for a fingerprint plot leave out “--local”
$ bowtie2 –local \
-x X_ \
-U /path/to/fastq/file/X_1063296.fastq \
-S X_1063296.sam
# to align all maternal FASTA files in the folder, to do a global alignment for fingerprint plot
leave out “--local”
indices=("1_" "2_" "3_" "4_" "5_" "6_" "7_" "8_" "9_" "10_" "11_" "12_" "13_" "14_" "15_"
"16_" "17_" "18_" "19_" "20_" "21_" "22_" "X_")

for i in ${indices[@]}; do bowtie2 --local -x $i -U
~/Documents/ENCODE/AnalysisFolder/SequencingData/merged_3296_3300/merged_h3k36.f
astq -S $i.sam; done;
# convert SAM format to BAM. Chromosome X as an example:
samtools view -h -S -b X_h3k36.sam > X_h3k36.bam
# Convert all SAM files to BAM in one step:
$for i in *.sam; do samtools view -b -S -h $i > bam_files/${i:0:2}.bam; done;
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Calculating uniquely mapped reads
The percent of uniquely mapped reads for a given ChIP-seq dataset is used to
determine whether excessive PCR duplications might have occurred. A uniquely mapped
read should have its own start and endpoint. PCR duplicates will start and end from the
same location. The greater the percentage of uniquely mapped reads the better the dataset
is. To calculate this, alignment files were sorted using Sambamba (Resources: 9Sambamba). Then unmapped and duplicate reads are excluded by filtering. This results in
an alignment file of just unique reads (Table 9). Samtools count function is used to count
the number of alignments in the uniquely mapped alignment file (Resources 10 Samtools). This is compared to both total reads and total aligned reads to get two
percentages (Uniquely Mapped Reads/ Total Reads or Uniquely Mapped Reads/ Total
Mapped Reads). Total mapped reads were computed using Samtools. Total reads,
whether they align or not, are shown in the summary output of FastQC.
Table 9 - Calculating Uniquely Mapped Reads
Table 9 - Calculating Uniquely Mapped Reads
# sort reads by index using Sambamba. “reads.bam” signifies any of the user’s BAM files
generated post alignment
$sambamba sort -t 2 reads.bam > sorted.bam
# take all alignments that are neither unmapped or duplicate reads and save them as a file called
unique.bam
$ sambamba view -h -t 2 -f bam \
-F "[XS] == null and not unmapped and not duplicate" sorted.bam > unique.bam
# to count only mapped reads
$ samtools view -c -F 260 sorted.bam
$ samtools view -c -F 260 unique.bam
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Rendering fingerprint plots for maternal X
Fingerprint plots are used to indicate the enrichment of immunoprecipitated DNA
versus background control genomic DNA. To create a fingerprint plot run SRR1063336
was used as an input control. Both datasets were filtered using fastq_quality_filter and
locally aligned to the X chromosome using Bowtie2 (Resources: 11-Bowtie2)(Table 10).
These alignment files were then sorted and indexed using Samtools. Deeptool’s
plotFingerprint command was used to generate the fingerprint plot (Resources: 2Deeptools). Because H3K36me3 is a chromatin mark that tends to be broadly distributed,
it was unlikely that it would render a fingerprint plot with the desired clear separation
between H3K36me3 target and background genomic DNA. For this reason, plots were
also rendered using CTCF and H3K4me3 datasets from the ENCODE project.
Table 10 - Create Fingerprint Plot
Table 10 - Create Fingerprint Plot
# sort BAM files (input and immunoprecipitated data)
$ samtools sort X_immunoprecipitated.bam -o sorted_X.bam
$ samtools sort X_control.bam -o sorted_X_control.bam
# index BAM files
$ samtools index sorted_X.bam
$ samtools index sorted_X_control.bam
# plotFingerprint
$ plotFingerprint -b sorted_X.bam sorted_X_control.bam -plot fingerprint.png

AlleleSeq
The two main steps of AlleleSeq are building the phased genome using
VCF2diploid and running the AlleleSeq pipeline (Downloads: 13-AlleleSeq and VCF
Diploid). As there is already a phased genome for GM12878, the use of VCF2diploid is
not covered here. The main steps to set up this software were to setup a directory
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structure to house all necessary files, organize and index files in GenomeFolder, acquire
cnv.calls and snv.calls files, and to modify a make file. Before setup, it is important to
install Python 2 (2.5.1 or greater) and Bowtie1 (version 0.10.0.2) (Resources: 14-Python
2) (Resources: 15: Bowtie1). Both of these must be added to PATH in bashrc.
Folder organization. AlleleSeq runs from a make file called PIPELINE.mk, which
describes in its header the directory paths of relevant files and folders. Because of this, all
files that run with AlleleSeq have to be organized and PIPELINE.mk has to be changed
to exactly match all directory paths. Figure 8 shows one working organization structure
for clarity. A new main folder was created called AnalysisFolder. This will be the home
directory where all programs, data, and results are stored. AnalysisFolder contains three
subfolders. The first subfolder should be an unzipped version of AlleleSeq, which has
been renamed “AlleleSeqPipeline”. The second subfolder within AnalysisFolder is the
one containing the phased diploid genome of GM12878. This folder was indexed with
Bowtie2 in prior steps, but AlleleSeq runs on Bowtie1. To avoid confusion, another
folder was made from the original zip file. It was renamed “GenomeFolder” (Figure 8).
Zipped versions of the H3K36me3 and H3K27me3 FASTQ file was added to this folder
(file should end in fastq.gz). The last folder, named BedFolder, stores BED files
depicting the regions of genome annotations of interest. If the user elects to do genome
annotation after running AlleleSeq as described here, then the inner contents of
BedFolder do not matter. The use of BED files is covered in later in “Genome
Annotation” after processing with AlleleSeq.
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Figure 8: Folder Structure for AlleleSeq Setup Yellow indicates a file folder. Green
indicates a file. Red signifies multiple files of the same type.
Within GenomeFolder, the maternal and paternal X chromosome FASTA files
were indexed with Bowtie1. The resulting .ebwt files are moved into two new folders
named AltRefMother and AltRefFather, respectively. It is important in these steps that
naming conventions be followed exactly or AlleleSeq’s make file will not recognize the
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files. Any decision to rename folders or files to other names requires it also be changed in
PIPELINE.mk.
Table 11 - Genome Folder Indexing
Table 11 - Genome Folder Indexing
# Move into GenomeFolder. Index Maternal and Paternal X Chromosomes Separately. This
will produce .ebwt index files.
$cd GenomeFolder
$bowtie-build X_NA12878_maternal.fa AltRefMother
$bowtie-build X_NA12878_paternal.fa AltRefFather
# move the resulting index .ebwt files into two separate folders with GenomeFolder
$mkdir AltRefMother
$mkdir AltRefFather
$mv AltRefMother* AltRefMother
$mv AltRefFather* AltRefFather

Setting up cnv.calls and snv.calls. A variant call file (VCF) for GM12878 and a
Perl script called vcf2snp (which sits inside of AlleleSeqPipeline) can be used to generate
snv.calls. This file contains the locations of Single Nucleotide Variants for GM1878 and
its two parents. CNVnator is used to produce a cnv.calls file, which contains read depth
analysis over a list of SNP positions (Abyzov, 2011). Both of these file types can be
placed within GenomeFolder along with a gunzipped file of the ChIP-seq reads being
analyzed. For GM12878, both of these files are publicly available for download because
AlleleSeq was originally published on GM12878 data (Downloads: SNV.call and
CNV.call files). They simply need to be renamed and placed within GenomeFolder.
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Table 12 - Generating cnv.calls and snv.calls
Table 12 - Generating cnv.calls and snv.calls
# rename snv.calls file
$mv NA12878.hiseq.snp.call GenomeFolder/snv.calls
# rename cnv.calls file
$mv rd_4327183snps_na12878_hg19.txt GenomeFolder/cnv.calls

Table 13 - PIPELINE.mk Modifications to Match Depending on Folder Naming Scheme
Table 13 - PIPELINE.mk Modifications to Match Depending on Folder Naming Scheme
BASE=path/to/AnalysisFolder
PL:=$(BASE)/AlleleSeqPipeline
SNPS:=$(BASE)/GenomeFolder/snp.calls
CNVS:=$(BASE)/GenomeFolder/cnv.calls
BNDS:=$(BASE)/BedFolder/bed_X_genes.bed
MAPS:=$(BASE)/GenomeFolder/%s_NA12878.map
FDR_SIMS:=5
FDR_CUTOFF:=0.1
INDEX:=$(BASE)/GenomeFolder

Table 14 -Running AlleleSeq
Table 14 - Running AlleleSeq
$ cd GenomeFolder
$make -f path/to/PIPELINE.mk

Gene annotation
To determine where SNPs occur relative to genes, a BED file was made that
corresponds to the reference assembly hg19. The reason for this is the phased genome of
GM12878 was derived originally from hg19 and the paternal and maternal chain files in
GenomeFolder can be used to transfer coordinates back and forth from both the parental
and reference assemblies. The hg19 BED file was downloaded for all genes on
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chromosome X using the UCSC Table Browser (Resources: 17 UCSC Genome Folder).
This BED file was then converted to coordinates that would correspond to the phased
genome by converting coordinates of the BED file to both the maternal and paternal X
using CrossMap(Resources: 1-Crossmap).
Post AlleleSeq analysis changes slightly based on the epigenetic marker being
explored. For example, H3K36me3 is unique compared to other signatures because it
tends to be concentrated in the gene body. Therefore, the BED file used should cover
exons and any SNPs should be found within or near exons. H3K4me1 is also unique
because it tends to rest on enhancer regions. The BED file used should thus correspond to
these enhancers. This contrasts to other epigenetic modifications, which can be looked at
500bp upstream of the TSS (Balaton and Brown 2021). These settings can be adjusted in
the UCSC table browser when the BED file is first downloaded.
Table 15 -Adjusting BED File Coordinates to Phased Genome
Table 15 - Adjusting BED File Coordinates to Phased Genome
# transfer coordinates of the BED file
$CrossMap.py bed path/to/GenomeFolder/maternal.chain X_genes.bed out.bed
$CrossMap.py bed path/to/GenomeFolder/paternal.chain X_genes.bed out.bed

AnnotateAlleleSeq is a new program designed specifically for the purpose of
visualizing SNP allele counts from the output of AlleleSeq. AlleleSeq produces a tabular
file called counts.txt. The columns of this file correspond to the chromosome, the SNP
position, the Maternal and Paternal allele nucleotide, and the count of each nucleotide
that appears at that position for A, T, C, and G. AnnotateAlleleSeq reads this table and a
converted BED file and graphs the count or the percentage of alignments that correspond
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to the maternal or paternal allele using MatplotLib and Pandas. It takes the start and end
range of every gene in the BED file and reports if a particular SNP lies in the range of
that gene in the resulting graph. AnnotateAlleleSeq produces a saved folder with a bar
graph image for every SNP. In order to confirm that no genes explored are mislabelled,
AnnotateAlleleSeq is used with both a maternal and paternal BED file. Only gene calls in
agreement regardless of BED file are considered for later analysis.
Results

Dataset quality
Running FastQC revealed baseline information about the clonal merged
H3K36me3 dataset. Of 26,092,631 reads, none were flagged as poor quality. The merged
dataset had 46% GC content and read lengths ranged from 41 to 60 bp. FastQC’s “Per
Base Quality Sequence Quality”, which would signal if there were any problems with the
sequencer at the ends of reads, flagged no issues yet some drop off in quality is apparent
at the end of reads (Figure 9). Most reads had a mean quality score of about 39. This
corresponds to a base call accuracy of ~99.987%. The GC content matched FastQCs
expected algorithm and no bases were labeled as N. All reads appeared to be pre-trimmed
for sequencing adaptors as FastQC did not observe any adapter content.
FastQC flagged issues “Per Tile Sequence Quality”, “Per Base Sequence Content”,
“Sequencing Length Distribution, Sequence Duplication Levels”, and “Overrepresented
Sequences”. “Per Tile Sequence quality” is presented as a heat map where the deviation
from the average quality of each tile for each position of the read is reported. In the
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figure, blue signifies quality that is either at or above the average quality. Hotter colors
signify poorer quality. The “Per Tile Sequence Quality” map showed some issues around
base pair positions 11, 30, 33, 37. However, no tiles had consistently low quality for
these bases and most base pair positions did not have any drop in quality for any tiles.
“Per Base Sequence Content” revealed some enrichment for adenine and thymine. The
flag for “Sequencing Length Distribution”, “Sequence Duplication”, and
“Overrepresented Sequences” reveals there are a lot of duplicate reads and this is likely
because DNA was probed for SNPs prior to sequencing.
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Figure 9: FastQC Results a.) Per Base Sequence Quality shows that for the entire length of the
read the median read quality score is greater than 26. For most of the length of reads until read
lengths surpass 55 bp the median quality is above 36. Base pair positions 56 through 60 at the
end of the read have a range of quality scores that range from 4 to greater than 36. b.) Per Tile
Sequence Quality shows that the base pair positions 11, 30, 33, and 37 had reduced quality in a
few tiles. Overall, most tiles cover most-read positions with no drop in read quality d.) Per
Sequence Quality Scores show that most reads have a mean quality score of 39. d.)Per Base
Sequence Content shows enrichment of adenine and thymine. The lines for %A and %T are
above %C and %G. e.) Sequence Duplication Levels- The merged H3k36me3 dataset has high
levels of sequence duplication. After sequence duplication level is greater than 10 the top line is
"% total sequences" and the lower line is the "% deduplicated sequences." If duplicates were
removed read counts would be reduced to 30.12% of total reads. Almost 20% of sequences have a
duplication level greater than 10 and over 10% of reads have a sequence duplication level greater
than 100. 10% of reads have a sequence duplication level greater than 1k.

Of the 591,667 total reads that map to the X chromosome specifically, 491,122
map uniquely (83% uniquely mapped reads per total mapped reads to X). A fingerprint
plot of this dataset does not yield a curved plot with any discrepancy between it and the

83
input control, however. For contrast, two other fingerprint plots were made to show an
example H3K4me3 dataset with no probing or PCR enrichment. H3K4me3 tends to be
less broadly distributed and is more likely to show separation between input control and
target. In Figure 10, a little separation is visible between the curves of H3K4me3 and
input. As another example, a fingerprint plot was produced that shows
immunoprecipitation of CTCF, a transcription factor. Compared to other fingerprint plots
there is an expected greater separation between the input control and target. A subtle
increase in curve separation is seen in the CTCF plot compared to H3K4me3 (Figure 10).
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Figure 10: Fingerprint Plots Show Target Enrichment Compared to Control a.) Fingerprint
plot of merged clonal datasets of H3K36me3 in GM12878 shows no separation between input
and control and a square plot. Only the line representing input is visible. The plot does not show
the typical curve of a fingerprint plot because there is a lot of duplication in the dataset. b.)
Fingerprint plot of nonclonal GM12878 H3K4me3 from ENCODE. This plot shows a typical
curve for a fingerprint. There is little separation between H3K4me3 target and input control.
Input.bam overlaps H3K4.bam, but between rank 0.4 and 0.6 the line thickens as h3k4.bam peaks
through below. c.) Fingerprint plot for targeting CTCF. Compared to H3K4me3, CTCF has more
separation between target and input control. Input.bam overlaps ctcf.bam for most of the image,
but there is a visible gap between input.bam (upper) and ctcf.bam (lower) after rank 0.8.

AlleleSeq results
Both the merged FASTQ file from the H3K36me3 datasets and the H3K27me3
FASTQ file was run through AlleleSeq using default settings. For each FASTQ file, a file
of counts is produced that represents the number of maternal and paternal alignments at
each SNP. A graph was made for every SNP that depicts the maternal and paternal count
of ChIP-seq reads at that SNP for both H3K36me3 and H3K27me3. In the original study
where these datasets were made, Nag et al. observed that XIST was expressed from the
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paternal X in the GM12878 clone used in this study (Nag et al. 2013). Thus, the maternal
and paternal count of ChIP-seq reads corresponded to Xa and Xi read counts, respectively
For H3K36me3 SNPs found within silenced genes, 78.7% (37/47) of SNPs had
more reads phased to Xa than Xi. 21.2% of silenced gene H3K36me3 SNPs (10/47) had
greater or an equivalent number of reads on Xi compared to Xa. Silent genes were any
genes that were not suspected as potential or confirmed escape genes across several
studies (Katsir et al. 2019). 66.6% (4/6) of SNPs in confirmed escape genes, which were
confirmed as escapees by Katsir et al., had H3K36me3 signal on both Xa and Xi with
more on Xa (Katsir et al. 2019). 33.3% (2/6) of the SNPs in escape genes observed did
not meet this condition. For all H3K36me3 reads, 71% of reads skew to Xa.
In H3K27me3, 25.6% (11/43) of silenced gene SNPs had more H3K27me3 on Xi
compared to Xa. 74.4% (32/43) of SNPs in silenced genes had higher or equal read
counts of H3K27me3 on Xa compared to Xi. For SNPs within known escape genes, all of
the 5 SNPs had greater H3K27me3 signal on Xa. 63% of reads skew to Xa for all
H3K27me3 reads.
Only a fraction of the total reads aligned to Xi in H3K27me3 and H3K36me3.
The H3K36me3 dataset started with approximately 26 million reads. Of these, 75,000 of
them align to a SNP in snv.calls and approximately 22,000 of those reads phase to Xi.
This signifies a 99.9% decrease in reads from the original 26 million. Similarly, the
H3K27me3 dataset started at 8 million reads. AlleleSeq aligned approximately 48,000
reads to known SNPs and approximately 18,000 to Xi.
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Discussion

AlleleSeq results of H3K36me3 and H3K27me3 reveal several potential
drawbacks of using AlleleSeq for allele specific epigenetic analysis. For both epigenetic
marks, the phasing of reads to Xi or Xa did not match expectations based on knowing
whether a gene was an escapee or silenced. H3K36me3 is known as an activating histone
mark (Sousa et al. 2019). Therefore, for SNPs in silenced genes, it was expected that it
would be enriched on Xa and depleted or absent on Xi. However, this was the case in
only 78% of the SNPs observed. Additionally, it was predicted that SNPs that passed
over known escape genes would still have more H3K36me3 signal on Xa, but still have
signal on both Xa and Xi. This condition occurred in only 66.6% of the escape genes
observed.
Even fewer SNPs had the expected results when H3K27me3 data was analyzed.
H3K27me3 is a known repressive mark. There should be more H3K27me3 signal on Xi
than Xa regardless of whether SNPs are found within silenced genes or escape genes
(Balaton and Brown, 2021). This expected condition only occurred in 25.6% of the SNPs
observed in silenced genes. Unexpectedly, no escape gene SNPs were more enriched on
Xi than Xa.
AlleleSeq was not vetted for looking at histone data when it was originally
published, and these initial results might indicate that this tool is not suitable for allele
specific epigenetic analysis (Rozowsky et al. 2011). No escape or silenced gene SNP
signals for either H3K36me3 and H3K27me3 meet the aforementioned expected
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conditions 100% of the time. If the cause of this is not AlleleSeq, one might consider
whether the results might have improved if the public ChIP-seq datasets were optimized
for studying Xi when they were prepared. The majority of H3K27me3 reads align to Xa
instead of Xi, but Xi should be enriched for H3K27me3 regardless of escape status
(Balaton and Brown 2021). One possible reason for this is Xi has a more compact
structure than Xa, so it is possible that the histone mark was less available for chromatin
immunoprecipitation on Xi. This would cause there to be more signal on Xa, even though
Xi should be more enriched for that mark. However, this explanation seems less likely to
be the case in escape genes, which should have looser chromatin in order to allow for
transcription. No H3K27me3 escape gene SNPs meet this expected condition: all SNPs
are enriched for Xa, not Xi.
In general, none of the datasets were ideal for testing AlleleSeq because the
quality was mixed. FastQC results revealed that while the datasets had high read quality,
they also had high levels of repetition. This repetition is likely the result of the lock probe
enrichment prior to sequencing which PCR amplifies the targetted SNPs. Normally, a
ChIP-seq dataset will not have a lock probe enrichment. Unfortunately, Deeptool's
plotFingerprint, which is intended to visualize ChIP-seq input signal from background,
did not render a curved plot when this was tried for H3K36me3. This can be attributed to
lock probe enrichment causing high levels of repetition. It was not possible to infer the
success of chromatin immunoprecipitation from this figure.
While the lock probe step made it impossible to make a clear fingerprint plot, it is
not clear whether it affected the AlleleSeq results. In theory, the lock probe step need not
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introduce any enrichment or biases that would hinder the comparison between the
maternal and paternal allele. However, the Nag et al. study reveals that there was a total
of 36,456 SNPs that occurred over coding regions. Based on the diffuseness of
H3K36me3 and H3K27me3, there is a question of whether filtering for just SNPs in
coding regions could have removed potentially informative signals. Ideally, if probes
must be used to get sufficient enrichment it would be best if the probes were designed to
target SNPs over a broad range across the gene body in both known escapee and silenced
genes. If probes are not needed for the enrichment, it is best that filtering of SNPs be
performed via alignments rather than at the bench where time and material costs are
higher, and the chance of human error is greater.
Another concern was the size of the datasets. According to a study by Jung et al.,
25 million reads were needed in order to pick up most features for an H3K36me3 ChIPseq experiment (Jung et al. 2014). In order to bolster read counts, the SRR106300
dataset, which sequences the same target from the same clone, was merged with
SRR10632296. This brought the read count to about 26 million reads. However, based on
the original publication on AlleleSeq, which had mapped read counts between 30 and 60
million, this total read count of mapped and unmapped reads is low. Similarly, the
H3K27me3 dataset was only about 8 million reads. Jung et al. found that a read count of
40 to 50 million reads was the level of saturation in which no new epigenetic features
appeared in H3K27me3. Higher read counts for this dataset would have been preferred as
well. For all datasets, many SNPs have low read counts in both Xa and Xi. Strikingly,
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over 99.6% of reads do not get phased to Xi for both epigenetic marks. This would make
an inferential analysis of signal on just Xi difficult because of the high read loss.
A robust exploration of allele specific epigenetic data should cover a broad range
of epigenetic marks. The 2021 Balaton and Brown study looked at the correlation
between H3K36me3, H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3, and
DNA methylation with XCI status. All these epigenetic signatures were used to predict
XCI status, but the predictive importance of each signature appeared to vary by gene
(Balaton and Brown, 2021). Although an ideal future study would cover all of these
signatures, some epigenetic modifications might be prioritized because of their greater
predictive power for escape status. It is likely best to focus on euchromatin-associated
marks. The Balaton and Brown study found that in the two datasets explored the
euchromatin marks H3K36me3, H3K4me3, and H3K27ac showed significant differences
between silenced genes and escapes. Only one data set produced a sharp contrast when
heterochromatin marks were evaluated (H3K9me3 and H3K27me3) (Balaton and Brown,
2021). Based on this, AlleleSeq would be better accessed by also analyzing H3K4me3
and H3K27ac data.
Overall, a major concern with using allele specific analysis is finding suitable
datasets with enough reads. This is a challenge because of the need for clonality and
because only a subset of reads will actually pass over known SNPs, which further
increases the need for more reads. In the future, this type of work would best be pursued
with benchwork. It is also not apparent that with this shortcoming that allele specific
analysis should be chosen over relative analysis, which does not have these restrictions.
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Unlike allele specific analysis, relative analysis does not depend on the number of SNPs
or the position of SNPs. With allele specific analysis using AlleleSeq, one only sees a one
nucleotide-wide glimpse of where there is a chromatin signal. Using only AlleleSeq, it is
impossible to know whether the read counts at a SNP represent a position at the peak or
tail of a distribution of accumulated reads. In relative analysis, one is more likely to view
data using peak callers so the full width of the signal can be observed. Given these
difficulties and the unexpected AlleleSeq results, AlleleSeq is not recommended at this
time for analyzing Xi, even with the questionable quality of the datasets.
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CONCLUSIONS
In females with X-linked disorders, random X chromosome inactivation (XCI)
causes some cells to express only the variant allele while the healthy allele remains
silenced. Targeted reactivation of the silenced X-linked allele might help treat these
disorders by restoring healthy gene expression in these cells (Halmai et al. 2020,
Bhatnagar et al. 2014, Carrette et al. 2018). This work addressed two unmet needs for
studying targeted reactivation.
The first is the need for clarity on the stability of X inactivation in patient stem
cells. Prior studies show unstable and unpredictable patterns of X inactivation during
reprogramming (Kim et al. 2009; Marchetto et al. 2010). Sometimes the pattern of X
inactivation in somatic cells is maintained in reprogrammed daughter cells (reviewed in
Cheung et al. 2012; Ananiev et al. 2011; Amenduni et al. 2011; Pomp et al. 2011). In
other studies, the pattern of inactivation is erased or erodes over time and it becomes
difficult to create populations of differentiated cells with clonal expression (Kim et al.
2009; Marchetto et al. 2010). This creates a problem for using these cell models in
targeted reactivation experiments because it is then ambiguous whether silenced allele
expression is a result of reactivation or other phenomena. In that situation, it is not
possible to know whether targeted reactivation or a mixed population of cells (i.e. a
population that has both cells that silence the maternal X and cells that silence the
paternal) is the cause of expression in both maternal and paternal active alleles.
Therefore, a starting requirement for these experiments is stable and predictable XCI in
these models.

93
The second hurdle in studying targeted reactivation is the lack of aggregated
bioinformatic techniques specifically vetted for assessing epigenetic marks on the
silenced X chromosome. The need to look at silenced X chromosome specifically
introduces a set of dataset requirements and new steps to the normal ChIP-seq pipeline
for which there is little direct information to guide researchers. This study addressed both
the issue of determining the state of X inactivation in iPSCs and bioinformatics
techniques to study epigenetic marks on the silenced X chromosome via two specific
aims.
Aim 1 and the Current State of the Field

The purpose of Aim 1 was to identify whether CDKL5 expression coming from
the “inactive” allele of Man0855-01 iPSCs was due to a mixed population or XCI
instability caused by a naive cell state. The mixed population hypothesis was evaluated
by looking at CDKl5 expression after doing a single clonal expansion of the original
population of iPSCs. Leaky expression due to partial XCI was tested by observing allelic
expression differences between iPSCs and neural stem cells (NSCs) that were
differentiated from the Man0855-01 iPSCs.
Both the results and approaches of Aim 1 fit with most of the current literature on
assessing the stability of XCI in pluripotent cells (reviewed in Cheung et al. 2012;
Ananiev et al. 2011; Amenduni et al. 2011; Pomp et al. 2011). However, some
differences reveal potential next steps and further questions in assessing iPSCs XCI
status.
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In 2011, Amenduni et al. also assessed iPSC model for CDKL5. Like this work,
they found that X-chromosome inactivation was sustained such that it was possible to
make clonal populations that express 100% of either the maternal or paternal allele of
CDKL5. Amenduni takes additional steps to assess XCI stability, however, rather than
focusing on just the expression of CDKL5 they also assessed overall X inactivation and
its temporal stability. To confirm the stability of X inactivation in these iPSCs they used
an androgen-receptor gene test with iPSC clones (Amenduni et al. 2011). This androgenreceptor gene assay is based on a 1992 paper that showed that the methylation patterns in
Hpa2 and Hha1 in the human androgen receptor gene correlated with X chromosome
inactivation (Allen et al. 1992). This looks at inactivation at a level below expression and
is less direct than looking at the expression of a single mutated allele because the purpose
is to determine overall X inactivation and not inactivation at a specific gene.
Another study also established clonal populations for a Rett Syndrome model but
with iPSCs that are isogenic for wildtype or mutant MECP2 (Ananiev et al. 2011). Other
Rett Syndrome disorder iPSCs somewhat contradict these results and show loss of
parental inactivation patterns in iPSC clones (Marchetto et al. 2010). Antibody stains for
H3K27me3, an inactivation mark characteristic of XCI, and Xist deposition show that at
least some iPSCs lose inactivation markers (Marchetto et al. 2010). This inactivation is
recovered when cells are neuronally differentiated (Marchetto et al. 2010). Yet, the same
study did find a few clones that did maintain XCI, which allowed for the formation of
clonal populations. What Aim 1 does not cover that has been explored to some depth in
the Marchetto study is what happens to XCI in iPSCs over time after several passages.
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One study revealed that XCI can be eroded over time at higher passage numbers. They
observed the XCI erosion by observing the loss of H3K27me3 foci and a loss of Xist
clouds (Mekhoubad et al. 2012). These effects can be permanent: even after
differentiation, some genes will continue to be de-repressed. This effect has already been
shown to create problems for modeling some X-related diseases and should be considered
(Mekhoubad et al. 2012).
Limitations and Recommendations of Aim 1

All of these studies and this work suggest that creating clonal iPSC populations
with complete XCI is possible, but it is not guaranteed. In order to work with an iPSC
model, it is necessary to assess XCI via expression to confirm clonality. It would also be
beneficial to assess overall XCI with approaches such as histone staining, Xist deposition,
and methylation patterns. Moreover, as these cells are kept over time this process must be
repeated.
These results support a mixed population hypothesis, but that does not imply no
relationship between XCI and pluripotency. Clearly, some iPSCs do not maintain XCI
after reprogramming. The cause of this is not well understood. If it is a pluripotent state
that can sometimes erase XCI patterns, it is reasonable to expect that that variance in the
reprogramming process such as levels of reprogramming factors themselves could affect
XCI.
To explore this hypothesis further it would be interesting to compare several
markers of XCI and pluripotency in two populations of iPSCs: one with stable XCI like
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the Man0855-01 iPSCs and another population that appears to have incomplete XCI. If
the hypothesis that the level of XCI correlates with reprogramming factor levels then
mRNA sequencing should reveal a relationship between pluripotency markers and the
expression of silenced genes. It would be useful also to look at other assays for
pluripotency like differentiation into all three germ layers to assess this as well.
Aim 2 and the Current State of the Field

The purpose of Aim 2 was to define and vet methods for analyzing histone
modifications in X-linked genes. Publicly available H3K36me3 and H3K27me3 ChIPseq data derived from GM12878 clones was used to illustrate the use of one aggregated
bioinformatics pipeline, which combined multiple tools. The overall analysis process first
addressed what were the experimental and raw data requirements for using open-source
data to ask allele specific questions about the X chromosome. When studying the silenced
X chromosome, allele specificity is required because the active X creates background
noise. The process then provides guidance on standard techniques for assessing the
quality of ChIP-seq. Last, it covers the use of AlleleSeq, a bioinformatics tool created by
the Gerstein lab, for looking at allele specific gene expression and binding (Rozowzky et
al. 2011). By stepping through this process, some suggestions and potential pitfalls were
revealed.
In Aim 2, a two-step process was used to look at allele specific differences in
escape and silenced genes using a clonal dataset of GM12878. First, the quality of reads
and chromatin immunoprecipitation was accessed for H3K36me3 using standard ChIP-
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seq quality control techniques. Then both H3K27me3 and H3K36me3 reads were
processed with AlleleSeq to determine signal on Xa and Xi. The results of aim 2 were
intended to illustrate this approach and to determine its limitations.
Part 1 of analysis showed that reads were consistently high quality. However,
there was a lot of repetitive sequence perhaps due to a lock probe step enrichment.
Fingerprint plots were used to assess how well immunoprecipitation worked by
comparing target to input control in H3K36me3. The plots created in this step showed
little to no visible difference between target and control when H3K36me3 data was
compared to ENCODE datasets for H3K4me3 and CTCF. H3K36me3 data does not
yield a normal fingerprint plot curve because of its high duplication levels. For this
reason, H3K4me3 and CTCF were used to illustrate how plots would look with normal
ChIP-seq data that has not been enriched. In general, broader histone marks are going to
create less of a clear separation on the plot between target and input control compared to
tightly distributed marks. The binding of transcription factors should have even more
separation. This is subtly visible for H3K4me3 and CTCF because CTCF does have the
most separation of the two, but even for a narrow mark like H3K4me3 and a binding
transcription factor like CTCF, the separation was poor on the graphs. This data suggests
that for broad histone marks this plot might not be informative enough to include. The
documentation on Deeptools plotfingerprint suggested weak plots could result from
broadly distributed marks as well (plotFingerprint).
Both H3K36me3 and H3K27me3 was used to assess the effectiveness of
AlleleSeq. The results showed two major issues. First, the phasing of reads to Xa or Xi

98
does not occur in an expected manner for all SNPs, regardless of the epigenetic mark or
whether the SNP is in an escape or silent gene. Second, most of the total reads are lost
once they have been filtered to SNPs that have been phased to Xi.
Better quality datasets might have improved these results. High levels of sequence
duplication did not allow for a curve to be created in the fingerprint plot. A lock probe
enrichment should not be used with this plot. Moreover, it is unclear from the labeling of
this public dataset whether the appropriate input control was used to compare with signal.
Another shortcoming of the datasets used is the read depth or the overall number of reads.
There is no recommended read count set for using ChIP-seq data in this type of allele
specific analysis yet. At the very least, it appears the target should be higher than 26
million (the size of the largest merged dataset), as most reads are lost. Lastly, AlleleSeq
might have been better accessed with more epigenetic marks such as H3K4me3 and
H3K27ac, which are known to be different between escape and silenced genes
(Balaton and Brown 2021).
Unfortunately, AlleleSeq will randomly sort a read to either allele if it does not
preferably match one rather than throwing the readout. In order to determine then
whether low signal is a result of random sorting or true but weak signal on the paternal X
it would be useful to observe whether that pattern holds when more reads are used. It
might be useful to rewrite this aspect of AlleleSeq as well to be able to toggle random
sorting versus skipping reads on and off.
Aim 2 takes a unique approach to looking at features on the X chromosome both
because it focuses on allele specificity rather than comparative normalized analysis of
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features. It also uses AlleleSeq differently than it was originally intended (Rozowsky et
al. 2011). Comparing the popularity of the relative analysis approach to the difficulties of
this approach does suggest that the allele specific approach should not be favored over
relative analysis.
Prior work on the differences between escape genes and silenced usually takes a
comparative analysis approach or it makes conclusions based on male samples. For
example, a 2019 study by Sousa and colleagues, which uses features as data points for
random forest predictive modeling to predict escapees, looks almost entirely at male
embryonic stem cell (ESC) ChIP-seq data (the only exception was HDAC3) (Sousa et al.
2019). This approach was applied because predictive modeling was being used on female
stem cells that had an inducible differentiation system. The original state of the
undifferentiated female ESCs was assumed to be similar to male. Unlike this study,
Sousa used a total of 58 public ChIP-seq libraries. Signals for each epigenetic feature
were normalized to a control experiment over a defined genomic region with normR.
Allele specificity is never used or considered, and this widened the total available
datasets this group could use because X expression clonality was not needed. This study
was one example of the relative analysis approach. The reason why this study of
epigenetic features is mentioned first is this study accomplishes what the next steps of
Aim 2 would be.
Other studies also take a relative signal rather than an allele specific approach. As
was described in the introduction of Chapter 3, a 2021 study by Balaton and Brown
compared the DNA methylation signal in males and females to infer escape gene status
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(Balaton and Brown 2021). High promoter methylation without a male control is also
sometimes enough to distinguish escape from silenced genes (Cotton et al. 2015). In
some cases, comparing the signal of two opposing histone marks, such as H3K36me3 and
H3K27me3 is enough to diagnose escape status (Balaton and Brown 2021). What makes
relative analysis ideal is the raw data needed for it does not have to be clonal or have
substantially high read counts. Even for a cell line as well characterized as GM12878, it
took an extensive search to find data that was ultimately subpar for this purpose. This is
likely why the approach is seen often in the literature. By contrast, currently there are no
other studies that look at chromatin signal in silenced and escape genes that use an allelespecific approach. Without benchwork, this obstacle would be one of the main challenges
if this approach was copied.
Another obstacle with allele specific approaches is that it depends on SNPs,
which are often limited and can occur anywhere in the genome. Rare SNPs are especially
less than ideal when the goal is to look at broadly distributed histone marks. When
AlleleSeq was published, Rozowsky et al looked at the binding of transcription factors
and polymerases, not histone modifications (Rozowsky et al. 2011). When observing
reads at a SNP level of resolution, there is no further information about where in a peak
of accumulated reads the SNP occurs. For this reason, any further study that uses
AlleleSeq might be improved with visual signals made from a peak caller even though
the peaks being viewed would not be allele specific.
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Limits and Recommendations of Aim 2

One of the main unanswered questions surrounding Aim 2 is whether further
research on the differences between escape and silenced genes should use an allele
specific approach or comparative analysis. This study reveals several shortcomings of the
allele specific approach. It is difficult to find clonal or highly skewed samples because
female XCI normally results in mosaic tissues. The need for higher read counts also
places additional demands in what datasets can be used. Finally, the lack of control on the
number of SNPs available or their placement relative to ChIP-seq signal is a barrier as
well. An enriched region could have no SNPs near it and be simply overlooked.
Aim 1 would benefit from bench work to determine whether deep sequencing of clonal
GM12878 ChIP-seq might give more statistically significant results. Combining several
datasets that look at the same target would give higher read counts and be more
conclusive.
The second route could be to continue work with open-source data but to focus on
comparative signal instead of allele specificity and see how it compares to allele specific
data. There are more datasets available to use, especially on ENCODE. It would be
possible to look at a wider variety of histone marks as well. With this approach higher
read counts are also less of a concern because reads are not split into two groups based on
allele matching.
With both of these approaches exploring other epigenetic marks beyond
H3K36me3 and H3K27me3 is important. Ideally all marks would be explored, but
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euchromatin associated marks appear to be the most important. One study found that
euchromatin associated H3K36me3, H3K4me3, and H3K27ac were the most different
between silenced and escape genes (Balaton and Brown 2021). For heterochromatin
marks the sharpest contrast was seen in H3K9m3e and H3K27me3 (Balaton and Brown
2021).
If either of these two paths lead to larger read counts for signal and possibly more
escapees, one interesting application of this work would be to use feature analysis in
predictive escapee or silenced modeling. As previously mentioned, Sousa et al. used this
approach with random forest to predict whether genes would be silenced or escaped in
mouse ESCs based on both epigenetic and genomic features (Sousa et al. 2019). Random
forest is a machine learning classification algorithm. It is composed of an ensemble of
decision trees that each contribute a classification prediction or vote. The total votes of
all decision trees are the classification result of the random forest. A decision tree is a
tree that classifies an observation into a predefined class. Branches are formed at each
node, which splits data into subgroups so that the intergroup differences are maximized
and the intra group differences are minimized. For classifying silenced versus escape
genes, a node might be whether H3K36me3 signal near the gene exceeds a certain
threshold or not. If that is a strongly predictive node one would expect it would
accurately separate known escapees from their silenced counterparts.
Sousa et al. never explored this in human cells or iPSCs in their study (Sousa et
al. 2019). One might recreate this approach to predict silencing that has already occurred
from various epigenetic markers in order to determine which features are most important
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for classification. For example, if one was looking at H3K36me3 signal's association with
escape genes one would first create a random forest model and train it on a dataset where
the model knows which genes are escapee or silenced. With the training, the model
would develop decision trees for classifying escapee status based in H3K36me3. One
would then test the blindfolded model by feeding it a yet unseen H3K36me3 dataset to
see if it correctly identifies escape genes or not. In this case, the model does not know the
true escape gene status, but the user does. The difference between the two can be used to
assess how well the model works. The features with the most predictive power would
also be the most biologically influential features.
Sousa et al also found that of all genomic and epigenetic features, distance from
Xist followed by gene density and proximity to line elements had the most predictive
power (Sousa et al. 2019). Whether this would also apply to human cells remains
unanswered. It is likely there could be differences in the power of different predictors
because mouse and human escape genes differ from each other in the way they are
clustered. Human escape genes tend to cluster while mouse genes are often found in
isolation (Fang et al. 2019).
Conclusion

Selective reactivation of X-linked genes has potential value for the treatment of
X-linked disorders. Further work in this field requires stable disease-relevant cell models,
like patient iPSCs and precise methods for analyzing the epigenetic state of X linked
genes.
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Through its aims this work illustrates an approach to evaluate the stability of XCI
in iPSC models. Uncertainty exists concerning the stability of reprogrammed cells and
this work finds a case in which XCI appears to be stable and provides a simple approach
for determining this in other iPSC populations. The existence of stable patient iPSCs and
simple ways to confirm clonality in new iPSC models is a boon for selective reactivation
studies. iPSCs allow for personalized medicine because they are exact genetic matches to
patients. With pluripotency, it is possible to determine whether reactivation benefits
disease affected cell types like neurons.
Deeper exploration of allele specific epigenetic marks on the X chromosome
reveals several obstacles of this approach. The first is that phasing between Xa and Xi
does not fit expected conditions 100% of the time. Another issue is acquiring larger
clonal datasets with greater than 25 million reads. Moreover, the need for SNPs presents
a limit on which genomic areas can be observed. For these reasons, relative analysis, an
approach that looks at differences between epigenetic marks between males or females or
between two different epigenetic marks is recommended.
Much of the ChIP-seq bioinformatics focused on in this work are a necessary part
of any reactivation study. Perfected methods would allow researchers to observe the
direct epigenetic effects of dCas9 attached effectors rather than only downstream
expression changes. Moreover, a danger of selective reactivation is causing the overexpression of genes. Observing the degree of epigenetic change caused by experiments
might allow for fine tuning of selective reactivation.

105
REFERENCES
Abyzov A, Urban AE, Snyder M, Gerstein M. 2011. CNVnator: an approach to discover,
genotype, and characterize typical and atypical CNVs from family and population
genome sequencing. Genome Res. 21(6):974–984. doi:10.1101/gr.114876.110.
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. 1992. Methylation of
HpaII and HhaI sites near the polymorphic CAG repeat in the human androgenreceptor gene correlates with X chromosome inactivation. Am J Hum Genet.
51(6):1229–1239.
Amenduni M, De Filippis R, Cheung AYL, Disciglio V, Epistolato MC, Ariani F, Mari
F, Mencarelli MA, Hayek Y, Renieri A, et al. 2011. iPS cells to model CDKL5related disorders. Eur J Hum Genet. 19(12):1246–1255.
doi:10.1038/ejhg.2011.131.
Ananiev G, Williams EC, Li H, Chang Q. 2011. Isogenic Pairs of Wild Type and Mutant
Induced Pluripotent Stem Cell (iPSC) Lines from Rett Syndrome Patients as In
Vitro Disease Model. PLoS ONE. 6(9):e25255.
doi:10.1371/journal.pone.0025255.
Anguera MC, Sadreyev R, Zhang Z, Szanto A, Payer B, Sheridan SD, Kwok S, Haggarty
SJ, Sur M, Alvarez J, et al. 2012. Molecular Signatures of Human Induced
Pluripotent Stem Cells Highlight Sex Differences and Cancer Genes. Cell Stem
Cell. 11(1):75–90. doi:10.1016/j.stem.2012.03.008.
Atri C, Guerfali FZ, Laouini D. 2019. Chapter 6 - MicroRNAs in diagnosis and
therapeutics. In: Mallick B, editor. AGO-Driven Non-Coding RNAs. Academic

106
Press. p. 137–177. [accessed 2022 Mar 18].
https://www.sciencedirect.com/science/article/pii/B9780128156698000063.
Bailey T, Krajewski P, Ladunga I, Lefebvre C, Li Q, Liu T, Madrigal P, Taslim C, Zhang
J. 2013. Practical guidelines for the comprehensive analysis of ChIP-seq data.
PLoS Comput Biol. 9(11):e1003326. doi:10.1371/journal.pcbi.1003326.
Balaton BP, Brown CJ. 2016. Escape Artists of the X Chromosome. Trends Genet.
32(6):348–359. doi:10.1016/j.tig.2016.03.007.
Balaton BP, Brown CJ. 2021. Contribution of genetic and epigenetic changes to escape
from X-chromosome inactivation. Epigenetics Chromatin. 14:30.
doi:10.1186/s13072-021-00404-9.
Barros de Andrade E Sousa L, Jonkers I, Syx L, Dunkel I, Chaumeil J, Picard C, Foret B,
Chen C-J, Lis JT, Heard E, et al. 2019. Kinetics of Xist-induced gene silencing
can be predicted from combinations of epigenetic and genomic features. Genome
Res. 29(7):1087–1099. doi:10.1101/gr.245027.118.
Berletch JB, Yang F, Xu J, Carrel L, Disteche CM. 2011. Genes that escape from X
inactivation. Hum Genet. 130(2):237–245. doi:10.1007/s00439-011-1011-z.
Bhatnagar S, Zhu X, Ou J, Lin L, Chamberlain L, Zhu LJ, Wajapeyee N, Green MR.
2014. Genetic and pharmacological reactivation of the mammalian inactive X
chromosome. Proc Natl Acad Sci U S A. 111(35):12591–12598.
doi:10.1073/pnas.1413620111.
Bonora G, Disteche CM. 2017. Structural aspects of the inactive X chromosome. Philos
Trans R Soc B Biol Sci. 372(1733):20160357. doi:10.1098/rstb.2016.0357.

107
Borsani G, Tonlorenzi R, Simmler MC, Dandolo L, Arnaud D, Capra V, Grompe M,
Pizzuti A, Muzny D, Lawrence C, et al. 1991. Characterization of a murine gene
expressed from the inactive X chromosome. Nature. 351(6324):325–329.
doi:10.1038/351325a0.
Brenes AJ, Yoshikawa H, Bensaddek D, Mirauta B, Seaton D, Hukelmann JL, Jiang H,
Stegle O, Lamond AI. 2021. Erosion of human X chromosome inactivation causes
major remodeling of the iPSC proteome. Cell Rep. 35(4):109032.
doi:10.1016/j.celrep.2021.109032.
Brockdorff N, Ashworth A, Kay GF, Cooper P, Smith S, McCabe VM, Norris DP, Penny
GD, Patel D, Rastan S. 1991. Conservation of position and exclusive expression
of mouse Xist from the inactive X chromosome. Nature. 351(6324):329–331.
doi:10.1038/351329a0.
Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, Willard HF.
1991. A gene from the region of the human X inactivation centre is expressed
exclusively from the inactive X chromosome. Nature. 349(6304):38–44.
doi:10.1038/349038a0.
Bruck T, Benvenisty N. 2011. Meta-analysis of the heterogeneity of X chromosome
inactivation in human pluripotent stem cells. Stem Cell Res. 6(2):187–193.
doi:10.1016/j.scr.2010.12.001.
Carrel L, Brown CJ. 2017. When the Lyon(ized chromosome) roars: ongoing expression
from an inactive X chromosome. Philos Trans R Soc B Biol Sci.
372(1733):20160355. doi:10.1098/rstb.2016.0355.

108
Carrel L, Willard HF. 2005. X-inactivation profile reveals extensive variability in Xlinked gene expression in females. Nature. 434(7031):400–404.
doi:10.1038/nature03479.
Carrette LLG, Wang C-Y, Wei C, Press W, Ma W, Kelleher RJ, Lee JT. 2018. A mixed
modality approach towards Xi reactivation for Rett syndrome and other X-linked
disorders. Proc Natl Acad Sci. 115(4):E668–E675. doi:10.1073/pnas.1715124115.
Chaumeil J, Le Baccon P, Wutz A, Heard E. 2006. A novel role for Xist RNA in the
formation of a repressive nuclear compartment into which genes are recruited
when silenced. Genes Dev. 20(16):2223–2237. doi:10.1101/gad.380906.
Chaumeil J, Okamoto I, Guggiari M, Heard E. 2002. Integrated kinetics of X
chromosome inactivation in differentiating embryonic stem cells. Cytogenet
Genome Res. 99(1–4):75–84. doi:10.1159/000071577.
Chen P-F, Chen T, Forman TE, Swanson AC, O’Kelly B, Dwyer SA, Buttermore ED,
Kleiman R, JS Carrington S, Lavery DJ, et al. 2021. Generation and
characterization of human induced pluripotent stem cells (iPSCs) from three male
and three female patients with CDKL5 Deficiency Disorder (CDD). Stem Cell
Res. 53:102276. doi:10.1016/j.scr.2021.102276.
Cheung A, Horvath L, Carrel L, Ellis J. 2012. X-Chromosome Inactivation in Rett
Syndrome Human Induced Pluripotent Stem Cells. Front Psychiatry. 3. [accessed
2022 Mar 19]. https://www.frontiersin.org/article/10.3389/fpsyt.2012.00024.
Cotton AM, Price EM, Jones MJ, Balaton BP, Kobor MS, Brown CJ. 2015. Landscape of
DNA methylation on the X chromosome reflects CpG density, functional

109
chromatin state and X-chromosome inactivation. Hum Mol Genet. 24(6):1528–
1539. doi:10.1093/hmg/ddu564.
Dandulakis MG, Meganathan K, Kroll KL, Bonni A, Constantino JN. 2016. Complexities
of X chromosome inactivation status in female human induced pluripotent stem
cells—a brief review and scientific update for autism research. J Neurodev
Disord. 8(1):22. doi:10.1186/s11689-016-9155-8.
Diaz A, Nellore A, Song JS. 2012. CHANCE: comprehensive software for quality control
and validation of ChIP-seq data. Genome Biol. 13(10):R98. doi:10.1186/gb-201213-10-r98.
Disteche CM, Berletch JB. 2015. X-chromosome inactivation and escape. J Genet.
94(4):591–599. doi:10.1007/s12041-015-0574-1.
Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ,
Hess JM, Gimelbrant AA, Beroukhim R, et al. 2017. Tumor-suppressor genes that
escape from X-inactivation contribute to cancer sex bias. Nat Genet. 49(1):10–16.
doi:10.1038/ng.3726.
Durbin RM, Altshuler D, Durbin RM, Abecasis GR, Bentley DR, Chakravarti A, Clark
AG, Collins FS, De La Vega FM, Donnelly P, et al. 2010. A map of human
genome variation from population-scale sequencing. Nature. 467(7319):1061–
1073. doi:10.1038/nature09534.
Escamilla-Del-Arenal M, da Rocha ST, Heard E. 2011. Evolutionary diversity and
developmental regulation of X-chromosome inactivation. Hum Genet.
130(2):307–327. doi:10.1007/s00439-011-1029-2.

110
Fang H, Disteche CM, Berletch JB. 2019. X Inactivation and Escape: Epigenetic and
Structural Features. Front Cell Dev Biol. 7:219. doi:10.3389/fcell.2019.00219.
FastQC Tutorial & FAQ. [accessed 2022b Dec 9].
https://rtsf.natsci.msu.edu/genomics/tech-notes/fastqc-tutorial-and-faq/.
Franco B, Thauvin-Robinet C. 2016. Update on oral-facial-digital syndromes (OFDS).
Cilia. 5:12. doi:10.1186/s13630-016-0034-4.
Garieri M, Stamoulis G, Blanc X, Falconnet E, Ribaux P, Borel C, Santoni F,
Antonarakis SE. 2018. Extensive cellular heterogeneity of X inactivation revealed
by single-cell allele-specific expression in human fibroblasts. Proc Natl Acad Sci
U S A. 115(51):13015–13020. doi:10.1073/pnas.1806811115.
Halmai JANM, Deng P, Gonzalez CE, Coggins NB, Cameron D, Carter JL, Buchanan
FKB, Waldo JJ, Lock SR, Anderson JD, et al. 2020. Artificial escape from XCI
by DNA methylation editing of the CDKL5 gene. Nucleic Acids Res.
48(5):2372–2387. doi:10.1093/nar/gkz1214.
Hansen RS, Canfield TK, Stanek AM, Keitges EA, Gartler SM. 1998. Reactivation of
XIST in Normal Fibroblasts and a Somatic Cell Hybrid: Abnormal Localization
of Xist RNA in Hybrid Cells. Proc Natl Acad Sci U S A. 95(9):5133–5138.
Huh I, Zeng J, Park T, Yi SV. 2013. DNA methylation and transcriptional noise.
Epigenetics Chromatin. 6(1):9. doi:10.1186/1756-8935-6-9.
Janiszewski A, Talon I, Chappell J, Collombet S, Song J, Geest ND, To SK, Bervoets G,
Marin-Bejar O, Provenzano C, et al. 2019 Sep 12. Dynamic reversal of random
X-Chromosome inactivation during iPSC reprogramming. Genome Res.

111
doi:10.1101/gr.249706.119. [accessed 2022 Mar 20].
https://genome.cshlp.org/content/early/2019/09/10/gr.249706.119.
Jung YL, Luquette LJ, Ho JWK, Ferrari F, Tolstorukov M, Minoda A, Issner R, Epstein
CB, Karpen GH, Kuroda MI, et al. 2014. Impact of sequencing depth in ChIP-seq
experiments. Nucleic Acids Res. 42(9):e74. doi:10.1093/nar/gku178.
Karlić R, Chung H-R, Lasserre J, Vlahoviček K, Vingron M. 2010. Histone modification
levels are predictive for gene expression. Proc Natl Acad Sci U S A.
107(7):2926–2931. doi:10.1073/pnas.0909344107.
Khetani MP Radhika. 2019 Apr 17. FastQC for quality assessment. Introd ChIP-Seq
Using High-Perform Comput. [accessed 2022 Dec 9].
https://hbctraining.github.io/Intro-to-ChIPseq/lessons/02_QC_FASTQC.html.
Kim D, Kim C-H, Moon J-I, Chung Y-G, Chang M-Y, Han B-S, Ko S, Yang E, Cha KY,
Lanza R, et al. 2009. Generation of Human Induced Pluripotent Stem Cells by
Direct Delivery of Reprogramming Proteins. Cell Stem Cell. 4(6):472–476.
doi:10.1016/j.stem.2009.05.005.
Krueger F, Andrews SR. 2016. SNPsplit: Allele-specific splitting of alignments between
genomes with known SNP genotypes. F1000Research. 5:1479.
doi:10.12688/f1000research.9037.2.
Kucera KS, Reddy TE, Pauli F, Gertz J, Logan JE, Myers RM, Willard HF. 2011. Allelespecific distribution of RNA polymerase II on female X chromosomes. Hum Mol
Genet. 20(20):3964–3973. doi:10.1093/hmg/ddr315.

112
Landt SG, Marinov GK, Kundaje A, Kheradpour P, Pauli F, Batzoglou S, Bernstein BE,
Bickel P, Brown JB, Cayting P, et al. 2012. ChIP-seq guidelines and practices of
the ENCODE and modENCODE consortia. Genome Res. 22(9):1813–1831.
doi:10.1101/gr.136184.111.
Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient
alignment of short DNA sequences to the human genome. Genome Biol.
10(3):R25. doi:10.1186/gb-2009-10-3-r25.
Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence
Alignment/Map format and SAMtools. Bioinformatics. 25(16):2078–2079.
doi:10.1093/bioinformatics/btp352.
Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, Shu J, Dadon D, Young RA,
Jaenisch R. 2016. Editing DNA Methylation in the Mammalian Genome. Cell.
167(1):233-247.e17. doi:10.1016/j.cell.2016.08.056.
Liu XS, Wu H, Krzisch M, Wu X, Graef J, Muffat J, Hnisz D, Li CH, Yuan B, Xu C, et
al. 2018. Rescue of Fragile X syndrome neurons by DNA methylation editing of
the FMR1 gene. Cell. 172(5):979-992.e6. doi:10.1016/j.cell.2018.01.012.
Lou S, Lee H-M, Qin H, Li J-W, Gao Z, Liu X, Chan LL, KL Lam V, So W-Y, Wang Y,
et al. 2014. Whole-genome bisulfite sequencing of multiple individuals reveals
complementary roles of promoter and gene body methylation in transcriptional
regulation. Genome Biol. 15(7):408. doi:10.1186/s13059-014-0408-0.

113
Lyon M. 1962. Sex Chromatin and Gene Action in the Mammalian X-Chromosome. am j
hum genet. 14(2):135–148.
Marchetto MCN, Carromeu C, Acab A, Yu D, Yeo G, Mu Y, Chen G, Gage FH, Muotri
AR. 2010. A model for neural development and treatment of Rett Syndrome using
human induced pluripotent stem cells. Cell. 143(4):527–539.
doi:10.1016/j.cell.2010.10.016.
Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, Eggan K. 2012. Erosion of
Dosage Compensation Impacts Human iPSC Disease Modeling. Cell Stem Cell.
10(5):595–609. doi:10.1016/j.stem.2012.02.014.
Migeon BR. 2020. X-linked diseases: susceptible females. Genet Med. 22(7):1156–1174.
doi:10.1038/s41436-020-0779-4.
Mo Z, Zecevic N. 2008. Is Pax6 Critical for Neurogenesis in the Human Fetal Brain?
Cereb Cortex N Y N 1991. 18(6):1455–1465. doi:10.1093/cercor/bhm181.
Mohsen A, Park J, Chen Y-A, Kawashima H, Mizuguchi K. 2019. Impact of quality
trimming on the efficiency of reads joining and diversity analysis of Illumina
paired-end reads in the context of QIIME1 and QIIME2 microbiome analysis
frameworks. BMC Bioinformatics. 20(1):581. doi:10.1186/s12859-019-3187-5.
Moore LD, Le T, Fan G. 2013. DNA Methylation and Its Basic Function.
Neuropsychopharmacology. 38(1):23–38. doi:10.1038/npp.2012.112.
Morita S, Horii T, Kimura M, Hatada I. 2020. Synergistic Upregulation of Target Genes
by TET1 and VP64 in the dCas9–SunTag Platform. Int J Mol Sci. 21(5):1574.
doi:10.3390/ijms21051574.

114
Negraes P, Trujillo C, Yu N et al. 2021. Altered network and rescue of human neurons
derived from individuals with early-onset genetic epilepsy. Mol Psychiatry.
26(11):7047–7068.doi:10.1038/s41380-021-01104-2
Nag A, Savova V, Fung H-L, Miron A, Yuan G-C, Zhang K, Gimelbrant AA. 2013.
Chromatin signature of widespread monoallelic expression. Gingeras T, editor.
eLife. 2:e01256. doi:10.7554/eLife.01256.
Nagamatsu G, Saito S, Kosaka T, Takubo K, Kinoshita T, Oya M, Horimoto K, Suda T.
2012. Optimal Ratio of Transcription Factors for Somatic Cell Reprogramming. J
Biol Chem. 287(43):36273–36282. doi:10.1074/jbc.M112.380683.
Napoles M de, Mermoud JE, Wakao R, Tang YA, Endoh M, Appanah R, Nesterova TB,
Silva J, Otte AP, Vidal M, et al. 2004. Polycomb Group Proteins Ring1A/B Link
Ubiquitylation of Histone H2A to Heritable Gene Silencing and X Inactivation.
Dev Cell. 7(5):663–676. doi:10.1016/j.devcel.2004.10.005.
Narayanan A, Gagliardi F, Gallotti AL, Mazzoleni S, Cominelli M, Fagnocchi L, Pala M,
Piras IS, Zordan P, Moretta N, et al. 2019. The proneural gene ASCL1 governs
the transcriptional subgroup affiliation in glioblastoma stem cells by directly
repressing the mesenchymal gene NDRG1. Cell Death Differ. 26(9):1813–1831.
doi:10.1038/s41418-018-0248-7.
Niwa H, Miyazaki J, Smith AG. 2000. Quantitative expression of Oct-3/4 defines
differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet.
24(4):372–376. doi:10.1038/74199.

115
Pagin M, Pernebrink M, Giubbolini S, Barone C, Sambruni G, Zhu Y, Chiara M,
Ottolenghi S, Pavesi G, Wei C-L, et al. 2021. Sox2 controls neural stem cell selfrenewal through a Fos-centered gene regulatory network. STEM CELLS.
39(8):1107–1119. doi:10.1002/stem.3373.
Panina Y, Germond A, Masui S, Watanabe TM. 2018. Validation of Common
Housekeeping Genes as Reference for qPCR Gene Expression Analysis During
iPS Reprogramming Process. Sci Rep. 8(1):8716. doi:10.1038/s41598-01826707-8.
Panning B. 2008. X-chromosome inactivation: the molecular basis of silencing. J Biol.
7(8):30. doi:10.1186/jbiol95.
Pasque V, Tchieu J, Karnik R, Uyeda M, Dimashkie AS, Case D, Papp B, Bonora G,
Patel S, Ho R, et al. 2014. X Chromosome Reactivation Dynamics Reveal Stages
of Reprogramming to Pluripotency. Cell. 159(7):1681–1697.
doi:10.1016/j.cell.2014.11.040.
Petropoulos S, Edsgärd D, Reinius B, Deng Q, Panula SP, Codeluppi S, Plaza Reyes A,
Linnarsson S, Sandberg R, Lanner F. 2016. Single-Cell RNA-Seq Reveals
Lineage and X Chromosome Dynamics in Human Preimplantation Embryos. Cell.
165(4):1012–1026. doi:10.1016/j.cell.2016.03.023.
Pezzella N, Bove G, Tammaro R, Franco B. 2022. OFD1 : One gene, several disorders. Am J
Med Genet C Semin Med Genet. 190(1):57–71. doi:10.1002/ajmg.c.31962.

116
Phred-scaled quality scores. GATK. [accessed 2022 May 6].
https://gatk.broadinstitute.org/hc/en-us/articles/360035531872-Phred-scaledquality-scores.
Plath K, Talbot D, Hamer KM, Otte AP, Yang TP, Jaenisch R, Panning B. 2004.
Developmentally regulated alterations in Polycomb repressive complex 1 proteins
on the inactive X chromosome. J Cell Biol. 167(6):1025–1035.
doi:10.1083/jcb.200409026.
plotFingerprint — deepTools 3.5.0 documentation. [accessed 2022 Jul 19].
https://deeptools.readthedocs.io/en/develop/content/tools/plotFingerprint.html.
Pomp O, Dreesen O, Leong DFM, Meller-Pomp O, Tan TT, Zhou F, Colman A. 2011.
Unexpected X Chromosome Skewing during Culture and Reprogramming of
Human Somatic Cells Can Be Alleviated by Exogenous Telomerase. Cell Stem
Cell. 9(2):156–165. doi:10.1016/j.stem.2011.06.004.
Pontier DB, Gribnau J. 2011. Xist regulation and function eXplored. Hum Genet.
130(2):223–236. doi:10.1007/s00439-011-1008-7.
Prothero KE, Stahl JM, Carrel L. 2009. Dosage compensation and gene expression on the
mammalian X chromosome: one plus one does not always equal two.
Chromosome Res Int J Mol Supramol Evol Asp Chromosome Biol. 17(5):637–
648. doi:10.1007/s10577-009-9063-9.
Quality Scores. 2018. NGS Anal. [accessed 2022 Dec 9].
https://learn.gencore.bio.nyu.edu/ngs-file-formats/quality-scores/.

117
Qu K, Zaba LC, Giresi PG, Li R, Longmire M, Kim YH, Greenleaf WJ, Chang HY.
2015. Individuality and Variation of Personal Regulomes in Primary Human T
Cells. Cell Syst. 1(1):51–61. doi:10.1016/j.cels.2015.06.003.
Radzisheuskaya A, Chia GLB, dos Santos RL, Theunissen TW, Castro LFC, Nichols J,
Silva JCR. 2013. A defined Oct4 level governs cell state transitions of
pluripotency entry and differentiation into all embryonic lineages. Nat Cell Biol.
15(6):579–590. doi:10.1038/ncb2742.
Radzisheuskaya A, Silva JCR. 2014. Do all roads lead to Oct4? The emerging concepts
of induced pluripotency. Trends Cell Biol. 24(5):275–284.
doi:10.1016/j.tcb.2013.11.010.
Rebuzzini P, Zuccotti M, Garagna S. 2020. X-Chromosome Inactivation during
Preimplantation Development and in Pluripotent Stem Cells. Cytogenet Genome
Res. 160(6):283–294. doi:10.1159/000508610.
Richard Albert J, Koike T, Younesy H, Thompson R, Bogutz AB, Karimi MM, Lorincz
MC. 2018. Development and application of an integrated allele-specific pipeline
for methylomic and epigenomic analysis (MEA). BMC Genomics. 19(1):463.
doi:10.1186/s12864-018-4835-2.
Rozowsky J, Abyzov A, Wang J, Alves P, Raha D, Harmanci A, Leng J, Bjornson R,
Kong Y, Kitabayashi N, et al. 2011. AlleleSeq: analysis of allele-specific
expression and binding in a network framework. Mol Syst Biol. 7:522.
doi:10.1038/msb.2011.54.

118
Sauteraud R, Stahl JM, James J, Englebright M, Chen F, Zhan X, Carrel L, Liu DJ. 2021
Aug 23. Inferring genes that escape X-Chromosome inactivation reveals
important contribution of variable escape genes to sex-biased diseases. Genome
Res. doi:10.1101/gr.275677.121. [accessed 2022 May 5].
https://genome.cshlp.org/content/early/2021/08/23/gr.275677.121.
Schulz EG, Meisig J, Nakamura T, Okamoto I, Sieber A, Picard C, Borensztein M,
Saitou M, Blüthgen N, Heard E. 2014. The Two Active X Chromosomes in
Female ESCs Block Exit from the Pluripotent State by Modulating the ESC
Signaling Network. Cell Stem Cell. 14(2):203–216.
doi:10.1016/j.stem.2013.11.022.
Sharp AJ, Stathaki E, Migliavacca E, Brahmachary M, Montgomery SB, Dupre Y,
Antonarakis SE. 2011. DNA methylation profiles of human active and inactive X
chromosomes. Genome Res. 21(10):1592–1600. doi:10.1101/gr.112680.110.
Shvetsova E, Sofronova A, Monajemi R, Gagalova K, Draisma HHM, White SJ, Santen
GWE, Chuva de Sousa Lopes SM, Heijmans BT, van Meurs J, et al. 2019.
Skewed X-inactivation is common in the general female population. Eur J Hum
Genet. 27(3):455–465. doi:10.1038/s41431-018-0291-3.
Silva J, Mak W, Zvetkova I, Appanah R, Nesterova TB, Webster Z, Peters AHFM,
Jenuwein T, Otte AP, Brockdorff N. 2003. Establishment of Histone H3
Methylation on the Inactive X Chromosome Requires Transient Recruitment of
Eed-Enx1 Polycomb Group Complexes. Dev Cell. 4(4):481–495.
doi:10.1016/S1534-5807(03)00068-6.

119
Stoler N, Nekrutenko A. 2021. Sequencing error profiles of Illumina sequencing
instruments. NAR Genomics Bioinforma. 3(1):lqab019.
doi:10.1093/nargab/lqab019.
Stresemann C, Lyko F. 2008. Modes of action of the DNA methyltransferase inhibitors
azacytidine and decitabine. Int J Cancer. 123(1):8–13. doi:10.1002/ijc.23607.
Takahashi K, Yamanaka S. 2006. Induction of Pluripotent Stem Cells from Mouse
Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 126(4):663–
676. doi:10.1016/j.cell.2006.07.024.
Telias M, Segal M. 2022. Editorial: Pathological hyperactivity and hyperexcitability in
the central nervous system. Front Mol Neurosci. 15. doi:
10.3389/fnmol.2022.955542
Tsuchiya KD, Greally JM, Yi Y, Noel KP, Truong J-P, Disteche CM. 2004. Comparative
Sequence and X-Inactivation Analyses of a Domain of Escape in Human Xp11.2
and the Conserved Segment in Mouse. Genome Res. 14(7):1275–1284.
doi:10.1101/gr.2575904.
Tukiainen T, Villani A-C, Yen A, Rivas MA, Marshall JL, Satija R, Aguirre M, Gauthier
L, Fleharty M, Kirby A, et al. 2017. Landscape of X chromosome inactivation
across human tissues. Nature. 550(7675):244–248. doi:10.1038/nature24265.
Vallot C, Ouimette J-F, Rougeulle C. 2016. Establishment of X chromosome inactivation
and epigenomic features of the inactive X depend on cellular contexts. BioEssays.
38(9):869–880. doi:10.1002/bies.201600121.

120
Vallot C, Patrat C, Collier AJ, Huret C, Casanova M, Liyakat Ali TM, Tosolini M,
Frydman N, Heard E, Rugg-Gunn PJ, et al. 2017. XACT Noncoding RNA
Competes with Xist in the Control of X Chromosome Activity during Human
Early Development. Cell Stem Cell. 20(1):102–111.
doi:10.1016/j.stem.2016.10.014.
van den Berg IM, Laven JSE, Stevens M, Jonkers I, Galjaard R-J, Gribnau J, Hikke van
Doorninck J. 2009. X Chromosome Inactivation Is Initiated in Human
Preimplantation Embryos. Am J Hum Genet. 84(6):771–779.
doi:10.1016/j.ajhg.2009.05.003.
Venolia L, Gartler SM, Wassman ER, Yen P, Mohandas T, Shapiro LJ. 1982.
Transformation with DNA from 5-azacytidine-reactivated X chromosomes. Proc
Natl Acad Sci U S A. 79(7):2352–2354.
Vinci L, Ravarino A, Fanos V, Naccarato AG, Senes G, Gerosa C, Bevilacqua G, Faa G,
Ambu R. 2016. Immunohistochemical Markers of Neural Progenitor Cells in the
Early Embryonic Human Cerebral Cortex. Eur J Histochem EJH. 60(1):2563.
doi:10.4081/ejh.2016.2563.
Vitale AM, Matigian NA, Ravishankar S, Bellette B, Wood SA, Wolvetang EJ, MackaySim A. 2012. Variability in the Generation of Induced Pluripotent Stem Cells:
Importance for Disease Modeling. Stem Cells Transl Med. 1(9):641–650.
doi:10.5966/sctm.2012-0043.

121
Wainer Katsir K, Linial M. 2019. Human genes escaping X-inactivation revealed by
single cell expression data. BMC Genomics. 20(1):201. doi:10.1186/s12864-0195507-6.
Wu B-K, Brenner C. 2014. Suppression of TET1-Dependent DNA Demethylation is
Essential for KRAS-Mediated Transformation. Cell Rep. 9(5):1827–1840.
doi:10.1016/j.celrep.2014.10.063.
Wutz A, Gribnau J. 2007. X inactivation Xplained. Curr Opin Genet Dev. 17(5):387–393.
doi:10.1016/j.gde.2007.08.001.
Wutz A, Jaenisch R. 2000. A Shift from Reversible to Irreversible X Inactivation Is
Triggered during ES Cell Differentiation. Mol Cell. 5(4):695–705.
doi:10.1016/S1097-2765(00)80248-8.
Younesy H, Möller T, Heravi-Moussavi A, Cheng JB, Costello JF, Lorincz MC, Karimi
MM, Jones SJM. 2014. ALEA: a toolbox for allele-specific epigenomics analysis.
Bioinformatics. 30(8):1172–1174. doi:10.1093/bioinformatics/btt744.
Zhang S, Cui W. 2014. Sox2, a key factor in the regulation of pluripotency and neural
differentiation. World J Stem Cells. 6(3):305–311. doi:10.4252/wjsc.v6.i3.305.
Zhao H, Sun Z, Wang J, Huang H, Kocher J-P, Wang L. 2014. CrossMap: a versatile tool
for coordinate conversion between genome assemblies. Bioinformatics.
30(7):1006–1007. doi:10.1093/bioinformatics/btt730.

122
APPENDICES
Appendix A: Resources for Aim 1
Table 16: NSC Media
Table 16: NSC Media
Name

Catalog Number

Gibco™ Neurobasal
Medium

Address
Thermo Fisher Scientific,

21103049

Waltham, MA
Thermo Fisher Scientific,

Glutamax

35050061

MEM Non-essential
Amino Acids (NEAA)

Waltham, MA
Thermo Fisher Scientific,

11140050

Waltham, MA)

SV30010

Cytiva, Marlborough, MA

Cytiva HyClone™
Penicillin Streptomycin
Solution

Thermo Fisher Scientific,
Gibco™ N-2 Supplement

17502048

Waltham, MA
R&D systems,

bFGF

233-FB-025

Gibco B-27 Supplement
(50X), serum free

Minneapolis, MN
Thermo Fisher Scientific,

17504044

Waltham, MA)
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Table 16: NSC Media
R&D Systems™ Human
EGF Recombinant Protein

R&D Systems™
236EG200

Minneapolis, MN

Sigma-Aldrich Insulin
Solution Human
Recombinant (10mg/ml)

Neta Scientific Hainesport,
SIAL-I9278-5ML

Gibco™ Glucose Solution
(D-Glucose)

NJ
Thermo Fisher Scientific,

A2494001

Waltham, MA)
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Appendix B: Resources for Aim 2
Table 17: Links to Resources for Aim 2
Resources

Link

1

Phased NA12878 Genome
(NA12878_diploid_2012_d
ec16.zip)
&
Variant Call File
(CEUTrio.HiSeq.WGS.b37.
bestPractices.phased.hg19.v
cf.gz)

http://sv.gersteinlab.org/NA12878_diploid/NA1
2878_diploid_2012_dec16/

2

NA12878 Escape Genes

https://staticcontent.springer.com/esm/art%3A10.1186%2Fs
12864-019-55076/MediaObjects/12864_2019_5507_MOESM6_
ESM.xlsx

3

Clonal GM12878 Data Sets
(PadLock Probe)

https://www.ncbi.nlm.nih.gov/Traces/study/?ac
c=PRJNA229064&o=acc_s%3Aa

4

SRA Toolkit

https://github.com/ncbi/sra-tools/wiki/02.Installing-SRA-Toolkit

5

CTCF Data

rep 1
https://www.encodeproject.org/files/ENCFF000
VUW/
rep 2
https://www.encodeproject.org/files/ENCFF000
VUU/
input
https://www.encodeproject.org/experiments/EN
CSR000EYX/

6

H3K4me3 Data Sets

rep 1
https://www.encodeproject.org/files/ENCFF825
QGB/

rep 2
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Resources

Link
https://www.encodeproject.org/files/ENCFF598
WCX/

input
https://www.encodeproject.org/experiments/EN
CSR142REC/
7

FastQC Tool

https://www.bioinformatics.babraham.ac.uk/pro
jects/fastqc/

8

FastX Toolkit

http://hannonlab.cshl.edu/fastx_toolkit/

9

Sambamba

https://github.com/biod/sambamba/releases

10

Samtools

http://www.htslib.org/download/

11

Bowtie2

http://bowtiebio.sourceforge.net/bowtie2/manual.shtml#obta
ining-bowtie-2

12

Deeptools

https://deeptools.readthedocs.io/en/develop/cont
ent/installation.html

13

AlleleSeq and vcf2diploid

http://alleleseq.gersteinlab.org/tools.html

14

Python 2

https://www.python.org/downloads/

15

Bowtie 1

https://sourceforge.net/projects/bowtiebio/files/bowtie/

16

SNV.call and CNV.call files http://alleleseq.gersteinlab.org/NA12878_diploi
d_dec16.2012.alleleseq.input.zip

17

UCSC Table Browser

https://genome.ucsc.edu/cgi-bin/hgTables

18

ChainSwap

https://hgdownload.soe.ucsc.edu/admin/exe/linu
x.x86_64.v369/

19

CrossMap

http://crossmap.sourceforge.net/

